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ABSTRACT
POLYMERIC NANOVACCINE DELIVERY SYSTEM FOR INFLUENZA VACCINE
CHAITANYA K. VALIVETI
2022
Vaccines are the most efficient and cost-effective method for preventing illnesses
caused by infectious pathogens. Even though the great success of vaccines over decades,
the development of safe and robust vaccines is still essential for emerging new pathogens,
re-evolving old pathogens, and improving the insufficient protection given by existing
vaccines. One of the most critical strategies for developing effective new vaccines is
selecting and using a suitable adjuvant or immune stimulant. Immunologic adjuvants are
essential for improving vaccine potency by enhancing the immune response of vaccine
antigens. The amount of antigen could be spared with improved potency, especially during
mass vaccinations in pandemics. In the past, our laboratory had discovered a plant-based
novel toll-like-receptor-4 agonist (adjuvant), inulin acetate (InAc), and showed that a
particulate delivery system using InAc is a potent vaccine delivery system that produces
strong humoral and cell-mediated immunity, which was tested in mouse models.

The study in this dissertation investigated the application of nanoparticles prepared
with inulin acetate nanoparticles (InAc-NPs) for dual functionality: as a delivery system
and vaccine adjuvant for enhancing mucosal and systemic immunity in mice and pigs. The
rationale behind selecting InAc-NPs is their established ability to stimulate strong systemic
immunity and a clear understanding of their activation mechanisms.
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In chapter II, we have established through subcutaneous vaccinations in swine for the first
time that inulin acetate nanoparticles (InAc-NPs) could generate high levels of systemic
antibodies (IgG) by using influenza antigens the extracellular domain of matrix protein 2
(M2e), and the influenza virus's surface membrane protein, Hemagglutinin (HA) protein.
InAC-NPs, as a vaccine delivery system, protected the antigen from degradation during the
storage and efficiently delivered it to swine macrophages (in-vitro). The antibodies
induced by InAc-NPs have a strong affinity and avidity to bind to HA. These antibodies
potentially prevent the virus from entering the host cell. The study introduced inulin acetate
(InAc) as a vaccine adjuvant in swine for subcutaneous vaccine delivery.

Chapter III, for the first time, established the efficacy of InAc-NPs as a vaccine delivery
system in a mouse for oral vaccines using influenza peptide (Inf-A) as a model antigen.
Importantly, InAc-NPs carrying the Inf-A produced higher mucosal and systemic
antibodies than unadjuvanted antigens in mice. InAc-NPs activated mouse macrophages to
secrete pro-inflammatory cytokines such as Interleukin-6 (IL-6) and macrophage
activation marker nitric oxide (NO).

In conclusion, we have demonstrated the capability of InAc-NPs as a robust vaccine
delivery and adjuvant platform for parenteral and oral vaccines that offer strong systemic
and mucosal immunity, which will have substantial implications in fighting several viral
diseases in humans and animals (pigs) in future.
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CHAPTER I
INTRODUCTION
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1.1. Components of the immune system
Two components of the immune system play critical roles in fighting against infection.
These are innate and adaptive immune responses. The process induces long-lasting
immunity against pathogens. The innate immune response reacts in a non-specific or
broadly specific manner, whereas the adaptive immune response reacts in a highly specific
manner (1). The innate immune response uses physical/chemical barriers and cells
involved in inflammation and phagocytosis to prevent the initial phase of pathogen
invasion. Physical barriers include skin and mucous secreted on the mucosal layer, whereas
examples of chemical barriers are chemicals such as bactericidal peptides and enzymes
secreted by the body's own cells, which also contribute to pathogen elimination (2, 3). The
innate immune response also utilizes soluble proteins such as complements to target
pathogen lysis and immune cells such as neutrophils, macrophages, natural killer cells
(NK-cells), and dendritic cells to cause pathogen destruction. The process of phagocytosis
utilizes the pattern recognition receptors (PRRs) in phagocytes for recognition and binding
to pathogen-associated molecular patterns (PAMPs) located on the pathogen cell exterior
parts. Alternatively, PRRs also recognize opsonized pathogens. Common opsonins include
complements and antibodies. The process of phagocytosis leads to the internalization of
the pathogens and fusion with lysosomes, where the pathogens are degraded by the
lysosomal enzymes (4, 5).
The adaptive immune response is an acquired immune response where both T and
B cells contribute equally to immune response. The hallmarks of adaptive immune
response include self/nonself-recognition, antigenic specificity, diversity, memory
response, and division of labor among B and T lymphocytes (6-8).
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The ability of adaptive immune response to produce the diversified population of
antibodies, each specific to a given antigen at the initial exposure, along with the
production of memory cells, contributes efficiently to the total elimination of pathogens
when the body is exposed to the same pathogen second time. The main participants in the
adaptive immune responses are the B lymphocytes which contribute to humoral immunity,
and T lymphocytes which contribute to cellular immunity. For the adaptive immune
response to occur, professional antigen-presenting cells are involved in the processing and
presenting of the antigen by major histocompatibility complex (MHC I and MHC II)
molecules. The internalized antigen gets into endocytic compartments of dendritic cells,
macrophages, which are presented to helper T cells as peptides to MHC II molecules. The
endogenously produced antigens in the cell's cytosolic compartment are presented to CD8+
T cells as peptides to MHC I molecules, thus letting the CD8+ lymphocytes recognize and
eliminate virally infected cells. (9, 10). This process causes signal transduction and releases
cytokines such as IL-4, IL-2, IL-5, and IFN-γ by T cells. These cytokines act on B and T
cells to drive cell differentiation and proliferation, leading to the generation of activated
effector T cells (Th1 response) and memory B cells (Th2 response).
Plasma cells secrete a large amount of antibodies to eliminate pathogens and are
short-span; the memory B cells are stored in the body for a more extended period (11).
Upon second exposure of the body to the pathogens, the memory cells are differentiated
into plasma cells capable of secreting antibodies in large amounts. The cytokines released
by the helper T cells also augment the cytotoxic T cell function. Thus, B cells produce a
humoral response; cytotoxic T cells mediate the cellular responses contribute to the
adaptive immune response, and help eliminate pathogens (7, 12-14).
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1.2. Vaccine
Vaccination is administering an antigenic component to stimulate an immune response to
protect the body against infectious diseases (15). Vaccine preparations may contain a
weakened form of the pathogen (bacteria, viruses, etc.) or protein or a toxin isolated from
the organism. Vaccines induce cellular and humoral responses that are part of adaptive
immune responses and prevent sickness from infection by pathogens. Ever since the
introduction of the smallpox vaccine by Edward Jenner in 1798, several vaccines have been
developed for a variety of infectious diseases. The vaccines developed for humans include
vaccines against Rotavirus, Hepatitis B, Diphtheria, Pertussis, Pneumococcus, Polio,
Influenza, Measles, Haemophilus influenza type b, Meningococcus, and Sars-cov-2 virus
to name few. Infectious diseases also affect animals such as pigs, dogs, cats, sheep,
chickens, fish, and cows. One of the pioneers who contributed to the development of animal
vaccines was Louis Pasteur. For example, between 1880 and 1885, he developed two
necessary vaccines: chicken cholera and rabies. The typical veterinary vaccines in use
today include Influenza, Porcine Circovirus Type 2, Pseudorabies, and Rabies.
Vaccines, when administered, activate the immune system to protect against
infectious diseases. The vital component of most vaccines is one or more proteins that
produce immune responses and offer protection. Some vaccines contain polysaccharide
antigens that can stimulate immune responses to prevent bacterial infections. The typical
examples in this category are pneumonia and meningitis caused by staphylococcus
pneumonia.
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1.3. Types of vaccines
Currently, six categories of vaccines are in use today in humans: 1) live attenuated
microorganisms; 2) inactivated whole microorganisms; 3) sub-unit vaccines (purified
protein, recombinant protein sub-unit, polysaccharide, polysaccharide/protein conjugates);
4) toxoids; 5) DNA and RNA vaccines and 6) viral vector-based vaccines (Fig.1.1). There
are apparent differences between live attenuated vaccines and inactivated vaccines. The
former may potentially replicate in an uncontrolled manner in people with
immunocompromised conditions, such as individuals with immuno-deficiencies, HIVinfected patients, or those treated with immune-suppressive drugs. This possesses some
degree of restrictions on their use.

Fig. 1.1. Different types of vaccines. Modified and adopted from the reference (16).
Traditionally vaccines are divided as live and non-live to differentiate by their presence
of attenuated replicating strains or killed pathogens. In addition to traditional vaccines,
new vaccine platforms are emerging.
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Attenuated live vaccines include rubella, measles, mumps, rotavirus, and polio.
One of the most significant advantages of the live attenuated vaccine is that the
microorganisms replicate sufficiently to elicit an immune response without causing
significant infectious symptoms. In contrast, inactivated vaccines do not pose any risk to
immune-compromised people.
Examples of non-live vaccines include the whole-cell pertussis vaccine and
inactivated polio vaccine. These preparations can be made through heat inactivation or
chemical treatment. Acellular pertussis vaccine is a purified protein vaccine. Some
recombinant protein vaccines include hepatitis B vaccine, and examples of toxoid vaccines
include inactivated protein toxins isolated from tetanus and diphtheria bacteria treated with
formaldehyde. It is essential to point out that other than whole virus vaccines or any
different strategy, it is often administered with an adjuvant to potentiate their
immunogenicity before administering to the body. In this regard, a few adjuvants are used
routinely in vaccine preparations. Traditional examples of adjuvants are an alum and its
salts. However, liposome-based adjuvants and oil-in-water (o/w) emulsions have recently
been used. An example of the o/w emulsion is MF59 used in influenza vaccines; another
example is AS01 used in shingle and malaria vaccines; ASO4 used in human papilloma
vaccines. Although the mechanism of action of adjuvants is not known, it is believed that
they provide danger signals mimicking those present in pathogens to the immune cells.
Vaccines may also contain ingredients that act as preservatives. Each excipient has
its benefit, the formulation, such as non-ionic surfactants that act as emulsifiers
(polysorbate-80) and stabilizers (gelatin or sorbitol). Other components used in the
manufacturing of vaccines may also be present in the vaccine as trace amounts. This may
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include antibiotics, yeast proteins, egg, formaldehyde/glutaraldehyde, latex, and pH
regulators (salts). Generally, these trace amounts of the components carried over to the
final preparation of the vaccine do not cause any harm to human health; however, in some
individuals, they may induce allergic reactions.
Vaccines protect the immunized individual through various mechanisms (Fig.1.2)
involving both B and T cells and the protection occurs mainly through the production of
antibodies. The vaccine induces immunological memory central to protection against
future infections. When the body encounters the pathogen for the second time, the memory
of immune response attained by vaccination to that particular pathogen mounts an immune
response faster and more robustly.
1.3.1. Protein vaccines
Most vaccines against infectious diseases consist of inactivated or live attenuated
pathogens. The attenuated and inactivated vaccines are considered conventional vaccines,
and vaccination using these have successfully decreased the incidence and burden of
several infectious diseases over the last several decades.
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Fig. 1.2. Generation of immune response to the vaccine. Modified and adopted from the
reference (16). The immune response is followed by administering the protein (antigen)
vaccine to muscle cells. The PRRs on the APCs recognize adjuvant as a danger signal and
initiate the immune response.
Attenuated vaccines, for example, viruses generally take years to develop because
a lot of time is required to isolate these viruses and subsequently adapt them in-vitro to
decrease their virulence. Cultivating the pathogens in specialized biosafety facilities may
also be challenging and adapting them to grow in such conditions. Purification and testing
of these attenuated vaccines may also require complex methods. In addition, attenuated
vaccines always have the risk of reversion and cause disease in humans. As mentioned
above, inactivated vaccines, on the other hand, need to be combined with adjuvants to
increase their immunogenicity as the danger signals are often lost during their preparation.
Because of these reasons development of traditional vaccines is a complex, expensive,
slow, and laborious process requiring substantial investment (17). It is estimated that the
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development of a conventional vaccine candidate is estimated to cost up to one billion
dollars before it can be mass-produced before entering the market. It is estimated that the
average time for developing a conventional vaccine from the pre-clinical phase to
marketing requires appx. Ten years and only 6% of them reach the market. The lengthy
time and the multiple and complex steps involved in manufacturing a conventional vaccine
necessitate the development of new strategies to accelerate the variety of vaccine platforms.
Therefore, traditional methods of manufacturing attenuated and inactivated vaccines are
ineffective in protecting the world population in contrast to both established and evolving
pathogens. In this regard, viral vector and DNA or RNA-based vaccine platforms have
been created to overcome vaccine challenges during the past few decades.
Attenuated or inactive whole microorganisms can induce a strong immune response
since they have both T and B cell epitopes presented in a way that mimics the pathogen.
Due to the weak immunogenicity of protein/peptide vaccines, they may need to perform
many immunizations to reach comparable efficacy to the whole virus vaccines.
Nevertheless, various approaches, such as presenting epitopes in various formats, have
been utilized to increase the effectiveness of subunit vaccines (e.g., nanoparticles or viruslike particles) or formulation with adjuvants. Peptides presented on MHCs should meet the
sequence of amino acid requirements; however, it is important to note every epitope is
immunogenic (18). Currently, Trimer (adjuvants; Matrix M), SCB-2019 trimer (adjuvants;
Alum+CpG 1018 or AS03) , Covax-19 (adjuvant; AdvaxCpG55.2), and SARS-CoV-2RBDN1C1 (adjuvants;Alum+CpG), recombinant vaccines are under clinical trials for
COVID-19 (19, 20).
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1.3.2. DNA and RNA vaccine
Nucleic acid vaccines: One of the vaccine platform already proven to be safe and effective
against infectious diseases are nucleic acid vaccines. They induce immune responses which
target only the selected antigen in the Pathogen. There are 2 types of nucleic acid vaccine:
RNA vaccine (as messenger RNA or mRNA) and DNA vaccine (plasmids). DNA vaccines
include a gene that encodes the desired part of a pathogen into a bacterial plasmid. DNA
vaccines can be delivered through intramuscular, intradermal, mucosal, and transdermal
routes. They contain plasmid DNA carrying the gene representing the gene of the antigen
encapsulated with lipid nanoparticles (LNPs). Once the DNA vaccines are administered,
the DNA is transferred to the nucleus of the cells (for example, professional APCs), where
it is transcribed; the mRNA produced is transported to the cytoplasm to produce the foreign
antigen (21). Upon expressing the foreign antigen, the professional APCs can degrade them
to peptides and then relocate to lymphoid structures (lymph nodes) for presenting the
antigen to resident cytotoxic T cells and Th CD4+ cells to mount an adaptive immune
response. Notably, the professional APCs may also acquire and process the foreign antigen
shed by other transfected cells at the injection site, eventually presenting the peptides to
the helper T cells.
The DNA vaccines is to deliver the load into the nucleus of the cell, DNA
transcription occurs and later translated into protein (antigen) in the cytoplasm. One
limitation of DNA vaccines is the comparatively low immune activation profile, which
hampers the required clinical effect. However, there are still safety concerns for DNA
vaccines. For example, the risk of generating anti-DNA antibodies will lead to autoimmune
disease conditions. Prior studies indicated that the (HBV) vaccine produced anti-DNA
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antibodies and activated autoimmune disorders (22, 23). Moreover, the major risk of DNA
vaccines is the possibility of incorporation into the host genome. This potentially causes
the mutations, which will be seen as malfunctioning or inactivating gene expression
(e.g.tumor suppressor gene) (24).
RNA vaccines are proven successful and could be explored for various infectious
diseases (25). RNA vaccines contain mRNA encapsulated LNPs. When injected into the
body, several cell types, including the APCs, take up these mRNAs, which undergo
translation and produce proteins in the cytoplasm. These proteins are then breakdown into
peptides and presented by MHCs to T cells. In addition to regular routes of antigen
presentation,

macrophages

can

present

the

antigens

generated

through

the

lysosomal/endosomal pathway via the MHC I molecules to the cytotoxic T cells (26).

1.4. Vaccine adjuvants
The adjuvant is part of a vaccine that enhances a more robust immune response.
In conjugate, recombinant, toxoid vaccines, and inactivated, adjuvants are employed
significantly for improved and long-lasting immune responses. Traditionally aluminumbased salts are used as adjuvants for commercially used vaccines. More adjuvants are
available but constrained to a few vaccines, e.g., CpG ODN, MF59, AS01, AS03, MF59,
and AS04 are FDA-approved vaccines for human consumption. So far, FDA-approved
adjuvants for commercial use are o/w emulsions (AS03 and MF59, aluminum salts, AS01)
(27).
The adjuvant molecular mechanisms by which they work still need to be explored
to understand better. However, the knowledge of the stimulation of the innate responses
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through PRRs is refining the effectiveness of adjuvants. The research studies also pointed
out that sensor activation (metabolic, nutrient) and tissue damage can regulate the innate
immune system to stimulate cellular or humoral immunity. Some of the adjuvants are
applied AS01 (malaria vaccine Mosquirix), AS03 (Pandemrix and Arepanrix), AS04
(human papilloma vaccine Cervarix), and CpG-1018 (hepatitis B vaccine Heplisav-B) (28).
These adjuvants are essential TLR receptor activators, usually present on APCs. In the late
1990s, it was found that stimulation of TLRs, which sense PAMPs in microbes, are the
source for activation of APCs, which in turn promotes antigen-specific (T and B cell)
reactions (29-32).
There are membrane-bound TLRs (TLR 1–TLR 13) that have been reported. So
far, TLR is known to identify the danger signals located on the cell membrane or the
endosomes. Lately, it has been reported cytosolic recognition systems such as RLRs and
NLRs. The RLRs are receptors that detect viral RNAs and control anti-viral systems by
IFN production (33). On the other hand, NLRs comprise several types, such as NOD1,
NOD2, and LRR (leucine-rich repeat) (33).
1.4.1. Toll-like receptors (TLRs)
Additional benefits of utilizing adjuvants are dose sparing, increasing vaccine efficacy in
older persons, and increasing the vaccine capability to work against variable pathogens by
eliciting a broader immune response. TLR agonists are urged to be used as an adjuvant
because of their ability to coordinate with adaptive immune response. TLRs are cell
membrane receptors primarily present on APCs. They are categorized into the cell
membrane (TLR 1,2,4,5 and 6) and intra-cellular TLRs (TLR3, 7 -9), present on endosomal
membranes (Fig.1.3.) (34). Bacterial lipopolysaccharide (LPS) has been shown as a ligand
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for TLR4 receptors and initiates the inflammatory signal (35). In one study, it was
demonstrated that TLR4 knockout mice did not respond to LPS in an in-vivo study (36).
The same trend was observed for (CpG) DNA; an agonist for TLR9 failed to stimulate in
the knockout model (37). The inherent downstream signaling pathways of mammalian
TLRs have been demonstrated in the picture (Fig.1.3). TLRs recruit the downstream
activating proteins after binding with the agonist. It included the TIR-containing adaptor
proteins molecule MyD88, which activated the MAP kinases and NF- kB signaling to
initiate articulation of TNF- α (38). The TLRs also can trigger IFN responses, for example,
IRF-3 and IRF-7, which perform an vital role in connecting innate and antigen-specific
immune activation by activating co-stimulatory fragments on immune cells (39, 40).

14
Fig. 1.3. TLR-activating adjuvants and the induced signaling pathway. Modified and
adopted from the reference (34). TLRs on the cell surface or intracellular targets for the
immunopotentiators (adjuvants). With the binding of ligand to the leucine-rich repeat,
TLRs recruit the proteins for activating the signaling pathway.
The inflammatory response trigger dendritic cells to induce local and systemic
inflammatory responses and produce pro-inflammatory cytokines, including TNF, and
Interleukin-6. The cytokines TNF initiate the stimulation of local endothelium to increase
vasodilation and raise the penetrability of the blood vessel, permitting serum proteins and
leukocytes to be recruited at the site of infection (41). Further, microbial spreading could
be prevented by coagulation factor III by initiating a coagulation cascade. Furthermore, the
stimulation of hepatocytes by IL-1β, along with IL-6, generates acute phase proteins with
collectins. These proteins help in phagocytosis by immune cells (antimicrobial response)
(41).
TLRs can also directly generate antimicrobial proteins by stimulating macrophages.
In mouse macrophages, nitric-oxide synthase (iNOS) is produced and has a vital role in
antimicrobial defense (42). Based on the current state of vaccines, weak immunogenic
subunit vaccines than whole virus vaccines are being utilized. To overcome this, addition
of adjuvant boosts immune response.
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TLR3 agonists
The TLR3 recognizes the dsRNA templets and promotes NF-kB production. The dsRNA
polyinosinic-polycytidylic acid (poly-IC) works by acting on TLR3 and RLRs, activating
innate immune response and stimulating the adaptive immune activation (34).

TLR4 agonists
Monophosphoryl Lipid (MPL)
The discovery of MPL as a TLR4 adjuvant accelerated the search for more adjuvants. MPL
was the first TLR agonist to receive licensed commercial use in vaccine preparation as an
adjuvant. The AS01 adjuvant, mixed with saponin and liposomes, is used in the herpes
vaccine (43). In addition, MPL is adsorbed on aluminum salts within the AS04 adjuvant,
used in the human papillomavirus vaccine Cervarix (44-47). MPL as an agonist, activate
TLR4, and APCs produce the NF-kB to release prominent cytokines, such as IL-6 and
TNF-α (proinflammatory). These produced proinflammatory markers enhance the immune
response by macrophage maturation, decrease the regulatory T-cell and suppress the
tolerance (48).

Inulin Acetate (InAc)
Our laboratory previously discovered a TLR4 agonist from a plant fiber inulin. Inulin is
modified to InAc to make it more active. (Fig. 1.4) (49). The TLR4 agonist activity studies
were established in multiple immune cells: microglia, dendritic, and peripheral blood
mononuclear cells (50-52). We observed that incubation of InAc with the above immune
cells could release pro-inflammatory cytokines. However, the InAc failed to activate
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immune cells in the presence of TLR4 antagonist or immune cells absent in TLR4 or
deficient in adapter proteins involved in TLR signaling (Mal/MyD88). The antigen
encapsulated water-insoluble particles of InAc mimicked the pathogen properties. They
offered improved antigen delivery compared to soluble antigen or antigen delivered
through poly(lactic-co-glycolic acid) (PLGA) particles (49). We named this “pathogenmimicking vaccine delivery system (PMVDS)” (50). The distinctiveness of PMVDS is
high antigen delivery to the APCs as an efficient vaccine delivery system, and concurrently
as an adjuvant, it activates the TLR4 on APCs to release the cytokines/chemokines. A
mouse study was conducted, and the PMVDS administered mice results suggested robust
stimulation of both humoral (>32 times vs. alum) and cellular immune responses to
encapsulated antigen (Ovalbumin). The InAc particles as a delivery system stimulated
strong cell-mediated immunity to provide protection in around 40% of the vaccinated mice
against tumor (B16-ova-Melanoma) progression (50, 51).

Fig. 1.4. Structure of Inulin Acetate. Modified and adopted from the reference (49). The
soluble form of inulin was modified to InAc by acetylating the hydroxyl groups. Inulin
acetate is water-insoluble, and its backbone structure (poly-fructose with beta
(2-->1) linkages in linear chains.
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Glucopyranosyl Lipid A in a Stable Emulsion (GLA-SE)
Based on the established MPL adjuvant properties, a second-generation of stable emulsion
with glucopyranosyl lipid A activated the TLR4 s. Evaluated the GLA-SE activity in
enhancing the H5N1 flu vaccine in clinical trial as an adjuvant. (53). In some other studies,
investigated GLA-SE for its adjuvant (combination with four proteins) activity with ID93
tuberculosis (TB) vaccine (54). Additionally, when the GLA-SE was combined with the
flu vaccine, Fluzone observed improved T cell and antibody levels and boosted the
specificity in evaluation with respect to Fluzone (55).

TLR5 agonists
Entolimod is a rprotein and a derivative of flagellin for pharmacological activity. The
TLR5 binds to bacterial flagellin, activates the NF-kB signaling and initiates the innate
immune response. In mouse studies, anti-tumor effects were started through the CD183dependent immune cell activation (56).

TLR7 agonists
Resiquimod, a dual agonist for TLR7/8, is a typical imidazoquinoline molecule (57). It
failed to elicit the local immune response while tested as an immunopotentiator in the
influenza vaccine against infectious diseases. However, due to its solubility, resiquimod
diffused quickly from the injection site to the nearby tissues and throughout the body.
In conclusion, the adjuvants combined with the subunit vaccines could potentially
stimulate the immune system. The immunopotentiator effect of adjuvants could be
explored in systemic or mucosal vaccines.
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1.5. Mucosal immunity: Oral and intranasal vaccination
The worldwide problem of morbidity and mortality related to infectious diseases,
especially mucosal viruses, is extreme. The severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) pandemic reminded the world of the constant threat of mucosal infectious
disease and the danger caused by many mucosal viral infections for which not many
vaccines exist. Due to the lack of effective vaccines, there is a need for vaccines for
respirational pathogens (58).
Respiratory pathogens persist as a leading cause of global deaths. The fourth
leading cause of death worldwide is respiratory tract infections and infecting around 2.4
million deaths per year. Few of the diseases were streptococcus pneumonia and influenza
virus, remarkably infecting the younger and older population (59). Currently, there is no
commercially available vaccine for respiratory syncytial (RSV) infection, most common
in younger people under 10 years (60, 61). Even though few commercial vaccines target
mucosal pathogens like bordetella pertussis, streptococcus P, and influenza virus, there is
still a need to enhance the vaccine effectiveness for protection, especially at the site of
infection. Studies show that the advanced mucosal vaccine strategy offers promising
treatments for these infections. For instance, for influenza vaccines, live attenuated doses
are given intranasally, and lately, these vaccines have become a central part of influenza
vaccination approaches, especially to children (62, 63); vaccines for B. pertussis are
administered intranasally and successfully enrolled for phase II (64, 65). The rise of SARSCoV-2 has strongly shown how fatal respiratory pathogens can be, with around two
hundred eighty million people infected and 5,400,000 deaths attributed to this pathogen
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(66, 67) and predicting that the pandemic will continuously impede the world economy,
especially third world countries (68, 69).
Even though there are multiple effective vaccines for SARS-CoV-2, there require
developing a vaccine; to meet the challenges posed by mass production and distribution.
To overcome the vaccination attempts in third-world countries, developing orally delivered
vaccines (SARS-CoV-2 or influenza) will improve convenience and compliance (70).
Although it is challenging to design the universal mucosal vaccines with conserved
antigens, it is a feasible option for preventing the upcoming pathogen infections (71).
Several microorganisms invade the mucosal routes (mouth and the upper
respiratory tract) and infect and lead to an alarming disease condition in the lower
respiratory tract. The upper respiratory tract's secretion of bactericidal enzymes and
mucociliary transport helps eradicate pathogens before reaching the lower respiratory tract.
Mucosal immunity comprises protection mechanisms comparable to the gastrointestinal
and respiratory tract (72).
Secretory IgA (sIgA), a dimer, is the primary secretory antibody secreted in mucous
fluids. sIgA lacks the complement activation or bacteriolytic effects (as IgG) because it
cannot destroy the pathogen. Alternatively, the neutralizing and agglutinating activity of
sIgA prevents the binding of pathogens to the cells. The pathogen bind by sIgA will be
cleared through mucociliary transport from the mucosal routes. sIgA is one of the
contributing factors in maintaining the upper respiratory tract homeostasis (immunological
and microbiological).
Some pathogens reside in the upper respiratory tract, including Streptococcus P.
and Haemophilus influenza. Increased colonization of these pathogens in healthy children
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leads to acute otitis media (AOM) & Otitis media with effusion (OME). Therefore, to
prevent these conditions, there is a need to develop mucosal vaccines that protect the
nasopharynx.
These vaccines elicited the only systemic immune response and were administered
through the subcutaneous route. To overcome this problem, administering through mucosal
routes (intranasal or oral) elicits better immune responses comprising mucosal level
immunity and systemic immune responses. One of the successful vaccines approved for
commercial use for flu and secondary AOM is FluMist. This vaccine contains live
attenuated influenza and is intranasally administered (73).

1.6. Lessons from licensed mucosal vaccines
In the past years in vaccine research, there has been a wide range of formulation types,
from the traditional whole-cell killed/attenuated vaccines to vector-based, nucleic acid
(DNA or RNA) or adjuvant subunit vaccines (74, 75). These changes will affect the
disadvantages of whole viral vaccines by introducing delivery systems and adjuvants.
However, the success rate of the mucosal vaccine is different than other routes in terms of
its efficacy. Of the nine mucosal vaccines (only live-attenuated or whole-cell inactivated
formulations) approved for human consumption, one is intranasal, and eight are orals
(Fig.1.5).
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Fig. 1.5. Successful platforms for mucosal vaccine design. Modified and adopted from
the reference (58). There are eight oral vaccines licensed against poliovirus, cholera,
rotavirus, and salmonella. So far, the whole virus vaccines (live attenuated and killed
vaccines) have demonstrated the effectiveness of mucosal vaccines.
The cholera toxin B subunit (CTB) was the first subunit antigen licensed as a
mucosal vaccine in 2004 as an added ingredient to the Dukoral (inactivated whole-cell
Vibrio cholerae vaccine). CTD is highly immunogenic and attaches part of cholera toxin;
(76-78) and binds with high affinity to ganglioside receptor (GM1) on epithelial cells.
Moreover, extrapolation of vaccine effectiveness from rodents to human beings can
be difficult because of variation in physiological conditions, including GI tract residence
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times, pH of the GI tract, and intestinal surface area. The vaccine ingredients need to be
considered based on the candidate’s capability of eliciting a mucosal response. When the
antigens are in the particulate form, whether as attenuated, whole bacterial cells, synthetic
particulate formulations, or virus-like particles, they are more potent in immunogenicity
than purified proteins. Further, the particulate nature enhances the uptake and targeting
APC site when mucosal is delivered. The nature of antigen uptake (Fig. 1.6) is a vital factor
when considering a vaccine candidate. The property of the antigen will determine the type
of immune activation, such as particulate, living, or soluble nature.
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Fig. 1.6. The nature of antigen uptake depends on the vaccine system. Modified and
adopted from the reference (58). Disposition of antigen uptake depends on the vaccine
components.
The immune homeostasis in mucosa due to tolerance plays a critical role in vaccine
effectiveness (79). The oral route is constantly exposed to different antigens procured from
the food and pathogens. This leads to oral tolerance and maintains the immune homeostasis
of the intestine (80). The gut tolerogenic can be caused due to acclimatization to
inflammatory conditions triggered by microorganisms (81) for innate immune response.
Combined with adjuvants in the vaccine will overcome the tolerance and induce innate and
adaptive immunity immune responses. However, more research needs to explore a
potential mucosal adjuvant. Few adjuvants are under investigation (Table.1.1) (82, 83).
Table. 1.1. Adjuvants and their targets
Composition

Target

Reference

Muramyl dipeptide (MDP)

TLR2

(84)

Monophosphoryl lipid A (MPLA)

TLR4

(85)

Flagellin

TLR5

(86)

Cholera toxin

GM1

(81)

Quillaja saponins

DCs

(87)

DCs uptake

(88)

Dimethyldioctadecylammonium (DDA)
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In conclusion, there is a need for safe and effective adjuvants to boost mucosal immunity
when administered with the antigen against respiratory viruses, including influenza viral
infection.

1.7. Influenza
Influenza (flu) is highly infectious and enters by respiratory tract and leads to
sickness. The influenza viruses contain a negative-sense RNA (ssRNA) genome and can
infect animals and humans. The difficulties of influenza can cause significant morbidity
and mortality. As per the recent information from the Center for Disease Control and
Prevention (CDC), it was estimated that there were 41 million illnesses, among them
140,000 – 710,000 hospitalizations and 12,000 – 52,000 deaths yearly between 2010 and
2020 (89, 90).
1.7.1. Structure and types of Influenza
So far, they have discovered 4 types of influenza viruses (A, B, C, and D) based on
their differences in antigen present on nucleoprotein and matrix protein. The influenza
genome is separated into different subtypes 8 types (A, B) or 7 types (C, D) influenza
strains. Out of all these strains, the major respiratory infections reported are caused by Type
A strain and lead to illness or death. There is a possibility of a new influenza epidemic or
pandemics. It is also reported that the influenza B strain can cause infection in humans. In
seasonal flu infections, influenza B lineages, B/Victoria and B/Yamagata, are used in
vaccine preparation due to their circulation annually (91). Influenza C viruses generally
trigger moderate symptoms. Influenza D infects small farm animals, including sheep,
swine, and cattle. There is limited data on how it infects humans (92-95). Influenza viruses
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have a filamentous or spherical shape. The influenza virus has surface lipid membrane
glycosylated proteins hemagglutinin (HA) and neuraminidase (NA) (Fig.1.7). The protein
unit number may vary between the different types of influenza based on the antigenicity
(96, 97).

Fig. 1.7. Structure of influenza virus. Modified and adopted from the reference (98).
Schematic representation of Influenza A virus, illustrating the location of different antigen
sites including surface glycoproteins, nonstructural, and nucleoproteins.

The influenza virus contains the lipid envelope membrane proteins and nonstructural protein 2 (NS 2), RNA segments layered with nucleoprotein (NP) in the RNA
complex. Influenza viruses are subdivided based on the surface HA and NA glycoproteins;
it has reported eighteen subtypes of HA and eleven subtypes of NA (98). The 3 proteins
(HA, NA, and M2) are present on the M1 lipid envelope. The M2 ion channel protein is
present in small numbers, around ten per hundred molecules of HA. On the other hand,
viruses have polymerase acid protein (PA) and RNA-dependent RNA polymerases (PB1
and are PB2) (99).
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1.7.2. Influenza vaccine
Vaccination signifies an effective and economically affordable way to restrict epidemics
caused by various viral infections like influenza and protects human health. Annual
influenza vaccine efficacy varies due to antigenic drift or shift. Influenza viruses undergo
genetic mutations and evade the immune system, and vaccine strains must be revised every
year. The effectiveness of commercial vaccines
The protective effects of the currently licensed vaccines differ annually (Fig. 1.8) and
depend on the antigenic similarity between the vaccine strains and viruses. The vaccine
efficacy can also be varied by the host immune system. For instance, elderly and young
individuals are more vulnerable to influenza infection (100-102).

Fig. 1.8. Seasonal influenza vaccine effectiveness from 2009 to 2019. Modified and
adopted from the reference (103). The efficacy of the annual flu vaccines depends on the
antigen match among the spreading strains and vaccine strain.
There are threats from the virus in multiple ways; it may be due to the risk of reevolving earlier endemic viruses and may be due to novel viruses emphasizing the need for
robust and cross-protective influenza vaccines. The interest in designing a new formulation
that effectively generates the neutralizing antibodies and provides cross protection could
be achieved by targeting the conserved regions of the virus (104-106).
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Research studies are in progress to develop vaccine formulation and move towards
a universal vaccine for influenza (Table. 1.2). The goal of designing the vaccine is to elicit
a cross-protection against different strains of influenza or the potential to work on mutated
novel strains and stimulate the long-term response.
Currently, there are multiple platforms or universal influenza vaccines in clinical
trials. New platforms have been developed using recombinant proteins, VLPs, or nucleic
acid-based delivery (107). Moreover, along with the conserved epitopes as HA,
extracellular domain of M2 and the NA, are also being studied. The conserved regions (M1
and NP) of influenza virus like M1 and NP, are also have under investigation for the
stimulation of cross protection by T cells (73).

1.8. Conclusion
In this dissertation, we are designing the nanovaccine particulate system for influenza
vaccines in swine to evaluate the vaccine efficacy in eliciting humoral immunity; and the
oral vaccine delivery system for influenza and investigating its mucosal immune response
against the vaccine antigen in mice.
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Table. 1.2. Currently licensed vaccines in the United States and Europe. Modified and
adopted from the following reference (103).
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Chapter II
Multifunctional Pathogen-Mimicking Vaccine Delivery System for Influenza
Vaccine
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2.1. Introduction
Viral diseases such as porcine reproductive and respiratory syndrome (PRRS), porcine
circovirus type 2 (PCV2), porcine epidemic diarrhea (PED), and influenza pose a severe
challenge to the productivity of today's swine farms (108, 109). Influenza viruses are
single-stranded RNA enveloped viruses of the family Orthomyxoviridae. Serological and
virological studies showed a 23- 28% prevalence of swine influenza in the swine
population of the Midwest and north-central united states. Influenza infection in pigs
causes weight loss, fever, cough, anorexia, and nasal discharge. Further influenza
infections in pigs increase the risk of transmission to humans. Often the best route for
managing viral diseases is prevention through efficient vaccines. However, not all viral
antigens are immunogenic enough to stimulate a potent immune response. Therefore,
immune-stimulatory agents called adjuvants have become an integral part of vaccines (29,
110, 111).
Adjuvants are molecule carriers dispensed with vaccines to enhance the immune
response. The adjuvants in the biological system will be recognized by the immune system
as a foreign antigens. The early responders in innate immunity to infection are APCs such
as dendritic cells (DCs), Langerhans cells, and macrophages will identify pathogens or
microbes through PRRs. PRRs are expressed both on the cell membranes and inside the
cells (112-114). The transmembrane receptors C-type lectin receptors (CLR), TLRs, and
NLRs are well-studied PRRs. They recognize PAMPs or MAMPs and DAMPs that initiate
the signaling to release cytokines and chemokines and alter the surface receptors that
modulate humoral and cellular immune responses. The activation of the TLR signaling
pathway is vital against influenza viral infection. Significantly among various TLRs,
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targeted activation via TLR4 ligands triggers instant defensive responses such as
inflammation and sets up antigen-specific immune responses which include humoral, and
cell mediated responses. Very few vaccine adjuvants are available which can stimulate
both humoral and cellular type immune responses (E.g., monophosphoryl lipid (MPL),
AS04 (it is a combination of aluminum hydroxide and monophosphoryl lipid A (MPLA)).
Nevertheless, these advanced adjuvants are too expensive for mass vaccinations for farm
animals (5, 33, 115-119).
To overcome the economic burden for farmers due to adjuvant cost, our laboratory
previously discovered inulin acetate (InAc), a plant-based polymer that acts as a novel
TLR4 agonist. Inulin acetate is an acetylated product of plant-derived polysaccharide
Inulin. The TLR4 agonist activity was established in multiple immune, microglial, and
peripheral blood mononuclear from human and swine origin. Antigen encapsulated in
micro- or nanoparticles prepared with InAc improved antigen delivery to dendritic cells
(49, 50).
The nanoparticle (NPs) based vaccine delivery platforms have successfully elicited
a robust immune response against the encapsulated antigen. The first step for any
successful vaccine is that the antigen must be internalized and processed by APCs. Being
particulate, the NPs containing the antigen are efficiently phagocytosed by the APCs.
Previously, our laboratory designed a novel nanoparticulate-based pathogen-mimicking
vaccine delivery system (PMVDS) using a TLR4 agonist InAc as a polymeric matrix to
target APCs such as dendritic cells (50). This dual mechanism of efficiently delivering
antigen to APCs and activating them through TLR4 produced robust humoral and cellmediated immune responses against the encapsulated antigen (ovalbumin) in mice (52).
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In adjuvant research, the success of an adjuvant in one animal species cannot be
extended to another species until proven. In this study, we are investigating the InAc as a
TLR4 adjuvant in pigs for the first time by designing an InAc-based nanoparticulate
influenza vaccine using surface protein hemagglutinin (HA) and extracellular peptide of
matrix protein (M2e) from Influenza-A/California/04/2009 (H1N1) as model antigens.
Testing the efficacy of an influenza vaccine in the swine model is also more clinically
relevant because of the immunological similarities between pigs and humans in terms of
structure and function. The humoral response was assessed as the antibody responses
against the HA, which has been established to be protective against influenza virus
infection (120). Similarly, a highly conserved ectodomain of M2e peptide has been selected
due to its conserved sequence among multiple variants of influenza, which could
potentially provide cross-protection between the various variants (121, 122). The study
establishes the application of a TLR4 based nanovaccine delivery system in delivering viral
vaccines in pigs.

2.2. Material and methods
2.2.1. Materials
Inulin (cat# 198971) and polyvinyl alcohol (cat# 151937) were purchased from MP
Biomedicals, Solon, Ohio. Poly (D, L-lactide-co-glycolide) (Resomer® RG 503,
cat#739952), albumin from chicken egg white, lyophilized powder (cat# A5503), and
albumin from bovine serum (cat# A3059) were obtained from Sigma-Aldrich, St. Louis,
MO. The M2e peptide (MSLLTEVETPTRNEWECRCSDSSD) was synthesized at
GenScript USA Inc., Piscataway, NJ. Fluorescein isothiocyanate isomer I (cat# sc-
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206015A) was purchased from Santa Cruz Biotechnology, Inc. Dallas, TX. Hemagglutinin
(HA) protein from Influenza A Virus, A/California/07/2009 (H1N1) pdm09, Recombinant
from Baculovirus (NR-51668), Anti-HA monoclonal antibodies (mAbs) [Anti-Influenza
Virus H1 Hemagglutinin (HA), A/California/04/2009 (H1N1) pdm09, Clone 5C12
(produced in vitro; cat#NR-42019], were obtained from BEI resources, ATCC, Manassas,
VA. AddaVax™ (cat#vac-adx-10) was purchased from Invivogen, San Diego, CA.
Immulon™ 4 HBX (cat#3855) clear plates were purchased from Thermo Scientific,
Waltham, MA, USA. Goat anti-porcine IgG-HRP conjugated secondary antibody (Cat#
6050-05) was purchased from Southern Biotech (Birmingham, Alabama, USA), Bethyl
Laboratories, Montgomery, TX. BD detergent solution concentrate (cat# 660585), BD
sheath additive (cat# 660584), and BD FACS clean (cat# 340345) were purchased from
BD Biosciences, San Jose, California. Magnesium Chloride (cat# BP214) and other
solvents and reagents were purchased from Fisher Scientific, Waltham, MA, USA.

2.2.2. Cell lines and animals
Pig alveolar macrophages (3D4/31) were obtained from ATCC (cat# CRL-2844™). Cells
were cultured in DMEM-high glucose medium (Hyclone Laboratories, Logan, Utah) and
supplemented with antibiotics (gentamycin and penicillin/streptomycin) and 10% fetal
bovine serum (FBS). The piglets (3-weeks old, either gender) were obtained from Midwest research swine (Yorkshire, cross-bred), Glencoe, MN, and housed according to the
approved South Dakota State University, IACUC protocol.
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2.2.3. Synthesis of fluorescein isothiocyanate labeled ovalbumin (FITC-Ova)
Twenty milligrams of fluorescein isothiocyanate (FITC) and 100 mg of Ovalbumin were
incubated in 10 mL of 220 mM sodium carbonate buffer (pH 9.5) for 8 hrs. The mixture
was dialyzed (SnakeSkin Tubing; 10 K.Da. cutoff, cat# 88245, Thermo fisher) against the
deionized water. The final solution was lyophilized and stored in the dark at 4 °C (123).

2.2.4. Synthesis of InAc polymer and preparation of InAc nanoparticles (InAcNPs)
InAc was synthesized and characterized using FT-IR, and InAc nanoparticles were
prepared as described previously (49). In brief, antigen (0.5 mg of HA, 3 mg of M2e, or 20
mg of FITC-Ova) dissolved in 200µl of 10 mM phosphate buffer (pH 7.4) was mixed with
50 µL of 2% Pluronic-F68 solution as a surfactant. The oil phase was prepared by
dissolving 100 mg of InAc in 5 mL of dichloromethane (DCM). The aqueous solution was
added dropwise to the InAc solution by vertexing to form a primary emulsion (w/o). Later,
the primary emulsion was added to water containing 0.5% w/v of polyvinyl alcohol as a
stabilizer (45 mL) with continuous stirring for 14 hrs. The precipitated particles were
collected via centrifugation (20,000g), lyophilized with 20 mg of mannitol as a
cryoprotectant, and stored at 4OC until further use. Nanoparticles were also prepared with
PLGA as a polymer and FITC-Ova as an antigen, as described above. HA and M2e
containing InAc-NPs were labelled as InAc-HA-NPs and InAc-M2e-NPs, respectively.
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2.2.5. Size, zeta potential, and morphology
The size and charge (ζ potential) nanoparticles were measured as described previously (49,
50)

2.2.6. Scanning electron microscope (SEM)
The morphology and size of InAc-NPs were examined using scanning electron
microscopy as described previously in (49, 50).

2.2.7. Determination of antigen loading
A weighed amount of antigen-loaded NPs was added to the acetone to dissolve the
polymer. The precipitated antigen was pelleted by centrifugation and dissolved in a 1%
sodium dodecyl sulfate (SDS) solution. The concentrations of extracted HA and M2e were
determined by the micro-BCA method (Micro BCA™ Protein Assay Kit; cat# 23235) and
in-house developed RP-HPLC method as described in section 2.2.8. The results are
reported as microgram of antigen per milligram of InAc-NPs.

2.2.8. Development of reverse phase HPLC method for the quantification of M2e
peptide
HPLC analysis was conducted using the Waters HPLC system (Milford, MA, USA) with
a W2998 PDA detector. A gradient method with the conditions described (Table.2.1) were
used to elute the peptide in the reverse phase using Syncronis C18 column (150×4.6 mm,
5 µm column) (Thermofisher, USA). The mobile phase-A contains 0.125% TFA in water,
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and the mobile phase-B contains 0.1% TFA in acetonitrile with a constant flow rate of 0.7
mL/min. The sample injection volume was 20µl, and the eluted peptide was detected at
220nm wavelength. From the chromatograms obtained from a known amount of the M2e
peptide (n=3) a standard curve was prepared which was used to determine the unknown
amounts in the sample.
Table.2.1. Gradient conditions for elution of M2e peptide
Time (minutes)

Flowrate

Mobile phase A

Mobile phase B

0.0

(mL/min)
0.7

95.0%

5.0%

7.0

0.7

25.0%

75.0%

13.0

0.7

95.0%

5.0%

2.2.9. Determination of endotoxin Levels
The presence of the endotoxins may interfere with the vaccine efficacy and its immune
assays. Therefore, the endotoxin levels in the formulation were assessed by the
commercially available ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit
[GenScript (Piscataway, NJ, USA)], and it is within the limits specified by the United
States Pharmacopeia (USP).

2.2.10. In-vitro antigen release
The InAc-M2e-NPs (1mg/mL) were dispersed in 0.1M phosphate-buffered saline (PBS) at
pH 7.4 and incubated at 37oC at 100 rpm using an orbital shaker. The samples were
collected and centrifuged at 20,000g for 15 minutes at pre-concluded time intervals. The
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supernatants were filtered (0.2 µm), and the amount of M2e released was determined by
RP-HPLC as described in section 2.2.8.

2.2.11 Storage stability of HA antigen
The antigen (HA) was stored as a solution from the commercial source or in InAc-NPs for
twelve months at 4oC. After storage, the antigen was extracted, as discussed in section
2.2.7. A freshly obtained recombinant HA solution (<1 month) was used to compare the
stability with the stored samples. Seven micrograms of protein samples were loaded onto
SDS-polyacrylamide gel electrophoresis (SDS-PAGE, 10 %). After separating the
proteins, the gels were stained with Coomassie Brilliant Blue (R-250) (0.25%) as described
by the manufacturer. The images of the stained gel were collected using Bio-RAD
molecular imager, ChemiDoc. XRS+ with Image lab software.

2.2.12. Antigen delivery by InAc-NPs to porcine macrophages
The uptake of InAc-NPs containing FITC-Ova by porcine macrophages was evaluated by
flow cytometry. The (3D4/31) porcine alveolar macrophages cells (1 × 10 6/well) were
seeded in a 24-well plate. The groups include no treatment (only media), InAc-FITC-OvaNPs, or PLGA-FITC-Ova-NPs for 1hr at 37oC. The amount of antigen added is normalized
to 25 g/well using the fluorescence of FITC-Ova. After incubation, cells were washed and
trypsinized. Subsequently, the percent of cells containing FITC-Ova and the relative
amount of FITC-Ova per cell were analyzed using flow cytometry.
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2.2.13. Immunization in piglets
The 3-weeks old littermate’s piglets with mixed gender and (n = 5 per group) were
immunized subcutaneously (s.c) with 25 µg of each antigen in 500 µl of vaccine
formulation using a 21G needle. The formulations were prepared as shown below (Table
2.2).
Table. 2.2. Formulation dilutions for pig immunization

The antigens were delivered with 3 different adjuvants/delivery systems: a) in saline
solution, b) encapsulated in InAc-NPs and suspended in saline, and c) in 50 % v/v
AddaVaxTM (squalene-based oil-in-water nano-emulsion) in saline. The blank particles
containing no antigen were used to eliminate the background immune response due to the
adjuvant. Primary immunization (day 1) was followed by one booster dose after 2 weeks.
The blood was collected 14 days post-immunization, and the serum was separated and
stored at -20oC until further use.

2.2.14. Determination of serum antibody titers
The antigen-specific antibody levels in the immunized pig serum were determined by the
indirect enzyme-linked immunosorbent assay (ELISA). The ELISA plates were coated
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with HA (1μg/well) protein or M2e peptide (~2μg/well) in sodium carbonate buffer, pH
9.2. Plates were sealed with parafilm to prevent evaporation and incubated overnight at
4oC. The plates were washed five times with a wash buffer (0.05 % Tween 20) and blocked
with a blocking solution containing 5% nonfat dry milk in PBS. Different dilutions of
serum samples containing the primary antibody were added to the wells and then incubated
for 2 hrs at room temperature. The plates were washed with wash buffer and incubated
with the anti-IgG pig secondary antibody for 1 hr before washing thrice with the wash
buffer. The plates were exposed to an HRP substrate (1-step Ultra EMB-ELIS) for 7
minutes. Finally, the stop solution was added, and measured the absorbance at 450 nm
wavelength.

2.2.15. Binding kinetics of anti-HA antibody from the immunized pig serum
The kinetic analysis was performed on Nicoya Open surface Plasmon Resonance (SPR)
using a carboxyl sensor following standard procedures. The instrument was primed with a
running buffer (PBS + 1% Tween 20 (PBST)) using a blank sensor chip without any surface
chemistry. The instrument separates the inserted sensor chip into two separate channels.
Channel-1 was coated with a control protein BSA and channel-2 with the target protein
HA for this experiment. The molecule coated on the sensor is called a ligand, and the
molecules that bind to the ligand are called analyte. Before coating with the ligand protein,
the sensor chip was surface conditioned by injecting 10mM HCL (pH 2) on both channels
at 150 µL/min. Subsequently, the carboxyl groups on the sensor were activated by injecting
a 1:1 ratio of EDC/NHS (10 mM) on both channels at 20µL/min. The optimized
concentration of recombinant HA protein (50 g/mL) dissolved in 10 mM acetate buffer,
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pH 5.6, was injected to only channel-2 at 20µL/min. The activated surface on channel-1
and any other open sites on channel-2 were blocked with two injections of 1% BSA
followed by one injection of Nicoya blocking solution. After the ligand immobilization,
the running buffer was switched to filtered 10% naïve pig serum in 1%PBST, and the
instrument was auto conditioned. The kinetics of antigen-antibody interactions were
established at first using a commercial anti-HA monoclonal antibody (anti-HA mAb,
analyte). The anti-HA mAb (100 L) was injected over both channels at 20L/min. The
binding response was measured as response units (RU). After each passage of the analyte
(antibody), the surface of the sensor was regenerated using magnesium chloride (4M) to
remove non-covalent interactions between the immobilized HA and the injected antibody.
Subsequently, the sensor was stabilized with the running buffer before injecting the next
analyte solution. The binding data were processed and evaluated by Trace drawer software
(ON, Canada). The Association (ka), dissociation (kd) rate constants, and equilibrium
dissociation constant (KD) were obtained by fitting a 1:1 ligand to the analyte binding
model. The experiment was repeated with different analyte concentrations (monoclonal
anti-HA antibody) and diluted serum (1 in 10) from the immunized and unimmunized
piglets. To confirm the consistency of the degree of availability of HA ligand molecules
on the surface, ant-HA mAbs at 10 µg/mL concentration was run intermittently. Each set
of experiments was completed on a single sensor.

2.2.16. Statistical analysis
The results were expressed as mean ± standard deviation (SD). The variance between
groups was compared using one-way ANOVA followed by Bonferroni's posthoc multiple
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comparison tests. The data was analyzed in Instant graph pad prism software (CA). P<0.05
was considered a statistically significant difference unless specified under figure legends.

2.3. Results & Discussion
Influenza viruses often cause acute respiratory infections in pigs. Influenza infections not
only produce significant economic losses for the global pig industry but also increases the
risk of zoonotic transmission to humans (124, 125). The transmission of infection from
swine to humans occurs due to the formation of novel influenza subtypes through genetic
assortment by mixing various flu viruses (Avian, porcine, human, e.t.c.) that could
potentially infect pigs. (126) Development of vaccines made a significant contribution to
reducing viral infectious disease and preventing death from infectious pathogens. While
designing the vaccine, one should consider the vaccine's efficacy and health, economic,
and social benefits (127). To overcome the problem and protect the pigs from severe
influenza infections, in this study, we have designed and tested a subunit influenza vaccine
using InAc-based polymeric nanoparticles as a vaccine adjuvant and delivery system. InAc
is an acetylated form of polysaccharide inulin established as a TLR4 agonist .
Previously, our laboratory has shown that the nanovaccine system utilizing the
InAc as a polymer made an efficient delivery of antigen to APCs and was able to robustly
stimulate both humoral (> 32 times vs. alum) and cell-mediated immune response in mice
. Based on these published reports, we utilized the InAc polymer to make a nanovaccine
particulate system and encapsulated the HA and M2e as antigens.
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2.3.1 Physicochemical characterization of the InAc polymer and vaccine
formulations
Inulin acetate was synthesized and characterized as described earlier (49, 50). The
acetylation was confirmed by the absence of hydroxyl groups in the polymer determined
by using FTIR (Fig. 2.1) and peak shift in 1H-NMR spectroscopy as described earlier (49).

Fig. 2.1. FTIR spectrum of inulin and inulin acetate. Indicating the disappearance of the
-OH peak of inulin (~ 3326 cm− 1) and the appearance of peaks for – C=O (~ 1743 cm−
1), -C-O (~ 1224 cm− 1), and for -CH3 groups (~ 1369 cm− 1) implying the acetylation of
inulin.
The M2e or HA-loaded nanoparticles were prepared using InAc as a polymer. The
size of InAc-HA-NPs and InAc-M2e-NPs were around 361 ± 0.52 and 327 ± 0.30 nm in
average diameter, respectively, and with a slightly neutral charge as determined by DLS
(Fig. 2.2 A, B, and Table. 2.3). Additionally, the shape (spherical) and size were further
confirmed by SEM (Fig.2.2 C).
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Fig. 2.2. Characterization of Inulin-acetate nanoparticles (InAc-HA-NPs). A) The mean
particle size distribution was measured using DLS and represented as intensity (percent).
B) Zeta potential shows an illustration of surface charge. C) The morphology of InAc-NPs
as shown by scanning electron microscopy (SEM).
Table. 2.3. Physicochemical properties of InAc-NPs.
Parameter

Blank

Blank

InAc-NPs

PLGA-NPs

Size (nm)

314 ± 0.62

297± 0.22

361 ± 0.52

327 ± 0.30

Zeta-potential (mv)

-0.8 ± 0.12

-1.7 ± 0.67

-1.2 ± 0.35

-0.6 ± 0.44

N/A

N/A

2.42 ± 0.2

2.071 ± 0.28

Loading (μg/mg)

InAc-HA-NPs InAc-M2e-NPs

A measured amount of InAc-NPs loaded with antigens were dissolved in acetone.
The precipitated antigens (HA and M2e) were pelleted by centrifugation and dissolved in
1% sodium dodecyl sulfate (SDS) solution as described in section 2.2.7. The extracted HA
& M2e amount was determined by RP-HPLC and micro-bicinchoninic acid (BCA) protein
assay (as per the manufacturer's instructions), respectively.
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The antigens selected are water-soluble, and the InAc is water-insoluble. As shown
previously, preparing NPs by using the double emulsion technique (w/o/w) provided higher
antigen encapsulation. The amount of HA and M2e antigens present in the NPs was
estimated by micro-BCA and HPLC methods, respectively. To determine the concentration
of M2e peptide, a new HPLC method was established (Fig. 2.3). The details of the
optimized method are described in section 2.2.8. Using the above methods, it was estimated
that 2.42 ± 0.2 and 2.071 ± 0.28 µg of HA and M2e antigens were present per milligram
of InAc-HA-NPs and InAc-M2e-NPs, respectively (Table.2.3). The use of nanoparticles to
deliver vaccine antigen(s) has several advantages: a) sustains the release of antigen, b)
improves antigen stability, c) targets the delivery to APCs, d) and being insoluble, enhances
the immunogenicity. The InAc-based nanovaccine delivery system is evaluated for the
above advantages in this study.

45
Fig. 2.3. Development of HPLC method for M2e peptide. A). Using the gradient program
(described in the methods section table 2.1), the peptide peak was eluted at 8.2 minutes
(Retention Time). B). The chromatograms were obtained at various amounts of The M2e
peptide was dissolved in phosphate buffer. C). The calibration curve was plotted from the
area under the curve of the peptide peak vs. the amount of the peptide.

2.3.2. Antigen release from InAc-NPs
It is known that hydrophilic macromolecules such as HA and M2e when
encapsulated, release from hydrophobic particles in a sustained pattern (51, 128). To model
the antigen release from InAc-NPs, M2e-encapsulated NPs were selected. As shown in
Fig.2.4, there was a burst release of around 20% of the antigen within 30 minutes of
incubation in PB, which may be due to a quick release of surface adsorbed peptide.
However, most of the antigen (~80 %) was released within 5 days of incubation. Although
peptide release from InAc-NPs was sustained over 3-5 days, it is much faster than the
reported release of another antigen (Ovalbumin) from InAc-NPs (~21 days) (50). The
differences in the release kinetics may be due to the smaller size of the M2e peptide (2.7
kDa.) compared to ovalbumin protein (45 kDa.).
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Fig. 2.4. In-vitro antigen (M2e) release from InAc-NPs. InAc-NPs (1 mg/mL) were
dispersed in 0.1M PB, pH 7.4 at ~100 RPM. M2e concentration in the soluble fraction was
measured at different time points using HPLC (n=3) as described in section 2.2.8.

2.3.3. InAc-NPs improve the stability of antigen
In subunit vaccines, the antigens are either peptides or proteins prone, which are to
proteolysis. Instability of vaccines/antigens is a major challenge during vaccine
development, vaccine transportation, or storage in third-world countries. The vaccine
formulation must preserve the stability of the antigen. The swine HA protein used in this
study is highly unstable and therefore, must be stored at <-80C to preserve its stability
(data not shown). One of the significant advantages of InAc-NPs based vaccines is that
they can be stored as a lyophilized powder. Therefore, we have evaluated the ability of
InAc-NPs to protect the HA protein by storing the HA protein at 4C either as a solution
(50 mM Tris-pH 8, 500 mM NaCl, and 10% glycerol) versus encapsulated in InAc-NPs as
a lyophilized powder. After 12 months of storage, the stability of HA was analyzed using
SDS-PAGE (Fig.2.5). The HA protein in the solution degraded completely, whereas
encapsulation inside InAc-NPs protected the protein. However, there is a slight degradation
in the encapsulated HA due to harsh encapsulation or extraction procedures used.
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Fig. 2.5. The ability of InAc-NPs to protect the antigen (HA) from degradation during
storage. The HA protein was stored at 4C as a solution or encapsulated inside InAc-HANPs. After 12 months, the protein was extracted from NPs as described in methods (section
2.2.7) and analyzed by SDS-PAGE followed by Coomassie blue staining. Lane ‘a’ and ‘b’,
HA solution (50 mM Tris, pH 8 with 500 mM NaCl and 10% glycerol), Lane ‘c’ and ‘d’,
InAc-HA-NPs, Lane ‘e’, molecular weight marker, Lane ‘f’, fresh HA protein solution (50
mM Tris, pH 8 with 500 mM NaCl and 10% glycerol).

2.3.4. InAc-NPs promoted internalization of antigen by swine macrophages
For an efficient vaccine response, the antigen needs to be processed and presented by
antigen-presenting cells (APCs) such as dendritic cells or macrophages. APCs are more
efficient in internalizing an insoluble antigen than a soluble one (129, 130). The nanosized
InAc-NPs mimic the size and shape of viruses or pathogens (Fig. 2.2). Further, the TLR4
agonistic activity of the InAc particles functions as PAMPs to enhance the recognition and
interaction by antigen-presenting cells. Nanoparticles encapsulated with a fluorescent
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antigen (FITC-labeled ovalbumin) were prepared using InAc or PLGA as a polymeric
matrix. The uptake of these particles by porcine alveolar macrophages was quantified by
flow cytometry. In general, porcine alveolar macrophages were less efficient in
phagocytosis than murine macrophages. After incubation for 1 hr with NPs, around 31 and
49 % of porcine macrophages tested positive for a detectable antigen for PLGA-NPs and
InAc-NPs, respectively (Table 2.4). However, previous studies have shown that 61% and
98 % of murine macrophages were positive for the same antigen when incubated with
PLGA-NPs and InAc-NPs, respectively (51). In all these experiments, PLGA-NPs was
used for comparison as they have similar size, shape, and lipophilicity as InAc-NPs.
However, InAc could activate TLR4 receptors on macrophages, whereas the PLGA is
immunologically inert and failed to activate macrophages (52). As shown here, InAc-NPs
were taken up by porcine macrophages 1.2 folds higher than PLGA-NPs (Fig. 2.6). The
increased uptake of the InAc-NPs by macrophages is likely to be mediated by the
recognition of the InAc by TLR4. These events may eventually contribute to potent
adaptive immune responses.
The size, shape, and rigidity of the particles also play a role in the internalization
by macrophages (131) (132). Further, nanoparticles are also elicited a stronger cytokine
response relative to microparticles (133). The particles with the size of 20- 100 nm range
will quickly enter the lymphatic system, while the particles ranging from 200-500 nm
(InAc-NPs in this study) have to be taken up by immune cells (Fig. 2.6), which gets
mobilized to the lymph nodes (134). Taken together, InAc-NPs provided additional
advantages as a nanovaccine delivery system by sustaining the release of antigen,
protecting it from degradation, and efficiently delivering it to macrophages.
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Fig. 2.6. Antigen delivery to porcine alveolar macrophages. The InAc-FITC-Ova-NPs or
PLGA-FITC-Ova-NPs (25µg equivalent to FITC-Ova) were added to 100,000 cells. After
1hr incubation, the cells were analyzed by flow cytometry for the presence of green
fluorescence. The data were represented as mean ± standard deviation (n=3).

Table. 2.4. Quantification of antigen delivery to pig alveolar macrophages
S.No.

Treatment groups

Mean fluorescence

% Green cells

intensity (MFI)
1.

Medium

8547.80 ± 32.5

13.24 ± 0.60

2.

PLGA-FITC-Ova-NPs

11453.85 ± 704.06

31.61 ± 3.07

3.

InAc-FITC-Ova-NPs

13958.40 ± 253.80

49.02 ± 3.32*

The data from Fig. 2.6. was quantified and reported. The MFI of FITC-Ova in the green
channel was fluorescence units (counts). Data represent the mean ± standard deviation (n
= 3). * p < 0.05 InAc-FITC-Ova-NPs vs. PLGA-FITC-Ova-NPs using one way-ANOVA
followed by Bonferroni's multiple comparison test.
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2.3.5. Antigen delivery by InAc-NPs generated strong antibody titers.
After establishing the efficacy of InAc-NPs using in-vitro, the ability of InAc-NPs to
induce the humoral responses in pigs was evaluated by immunizing 3-week-old piglets
through a subcutaneous route (2 doses of 25 g of antigens HA and M2e). The antigenspecific total IgG levels in serum collected 14 days after booster immunization was
determined by indirect ELISA. Antigens dissolved in saline, or along with a commercial
adjuvant Addavax were used as controls for comparison.

Fig. 2.7. Titers of HA (panel A) or M2e (panel B)-specific IgG antibodies in the serum.
Pigs (n = 5 per group) were immunized subcutaneously with HA and M2e (25 µg
each/dose; 2 doses) in saline or encapsulated in InAc-NPs or along with Addavax, and the
antibody titers in the srum collected 14-days post final immunization were determined by
using indirect ELISA. The titer is defined as a minimal experimental serum dilution at
which the absorbance is more than average absorbance plus two standard deviations from
the blank serum (no antigen). * p < 0.05 InAc-NPs vs. saline as an adjuvant using one wayANOVA followed by Bonferroni's multiple comparison test.
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InAc-NPs displayed significantly higher (*p < 0.05) anti-HA (4.7-fold) and antiM2e (1.7-fold) antibody titers than saline as an antigen delivery vehicle (Fig. 2.7). InAcNPs were able to generate similar antigen-specific serum antibody titers to a commercial
vaccine adjuvant (Addavax) (Fig. 2.7). Similar results were observed with InAc-NPs in
mice studies (50, 51). In mice, InAc particles have shown superior serum IgG antibody
response against the antigen compared to Alum (32 times) as an adjuvant (50). InAcmicroparticles formed a depot at the injection site despite being non-toxic. However, InAcNPs (200-300 nm) were cleared from the injection site within 30 hrs of injection (51),
which is beneficial in meat food-producing animals.
Serum antibodies can function in multiple ways to provide protection or quick
recovery from an infection. Antibodies can neutralize the virus and prevent its entry into
a host cell or through antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis
(ADCP); antibodies promote the clearance of the virus. In this study, InAc-NPs were able
to generate high titers of anti-HA or anti-M2e antibodies. HA protein is easily accessible
to antibody binding and thus leads to virus neutralization, unlike the M2e peptide. Despite
the failure to neutralize the virus (135-137), generating strong anti-M2e antibodies seems
to be effective against influenza infection, as evident by the protection shown with passive
transfer of M2e anti-serum or anti-M2e monoclonal antibodies (135, 138-140) or poor
protection of M2e vaccination in B cell-deficient mice despite generating strong CD4 T
cell response against M2e (141). Therefore, in this study, the presence of high levels of
serum antibodies against both HA and M2e peptides is expected to provide protection
against influenza (142).
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2.3.6. Antigen-specific serum antibodies generated by InAc-NPs have high
avidity.
For a vaccine to be successful in preventing or reducing the severity of a disease, in addition
to generating high levels of antibodies (Fig. 2.7), it is critical that the generated antibodies
must be of high quality (affinity and avidity) with respect to binding to the targeted antigen.
Avidity and affinity will determine the binding strength. Avidity is for determining the
total binding strength, and affinity is for determining the binding strength at a single
binding site. The Open-SPR was used to investigate and compare relative binding affinities
and kinetic parameters of antibodies present in immunized swine serum (with different
adjuvants) to an immobilized recombinant HA protein (H1 Hemagglutinin (HA) Protein
from Influenza A Virus, A/California/07/2009 (H1N1) pdm09, recombinant from
Baculovirus, NR-51668). SPR measurements are based on the mass and indicate the
proportional concentration of analyte bound to the ligand at a given concentration and a
defined flow rate to determine the binding interaction parameters (143). SPR can analyze
the association and dissociation phases of interaction and detect even weak binding events
(144, 145). The sensorgram indicates the different binding events, such as association and
dissociation phases of binding, which are indicated by rate constants, ka and kd, respectively
(Fig. 2.8 B). These parameters are used to determine the equilibrium dissociation constant
(kD) for the binding of a ligand (immobilized) to the analyte (in flow) using the
Tracedrawer software. The approximate amount of ligand to coat the chip surface was
calculated using the following formula:
ValencyLigand)/MassLigand.

Responsemax = ResponseLigand × Massanalyte ×
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Fig. 2.8. Schematic representation of Surface Plasmon Resonance (SPR) A) procedure
for injection of samples, ligand immobilization, and analyte binding B) demonstrating the
association (ka), dissociation (kd), and equilibrium rate constants (KD) in SPR sensorgram.

Before we analyze the polyclonal serum from the immunized pigs, we have
standardized the binding of anti-HA antibodies to an immobilized HA antigen using a
commercial anti-HA monoclonal antibody (NR-42019, BEI Resources). Various
concentrations of the mAb (2.08 nM to 33.33 nM) were injected over an immobilized HA
protein on an SPR sensor. The association and the dissociation phases of binding were
recorded (Fig. 2.9 A). The values of association rate constant (ka), dissociation rate constant
(kd), equilibrium dissociation binding constant (kD), and the maximum binding units were
calculated using Tracedrawer software. The antigen-specific antibody concentration was
determined using the binding response measured during early mass transport limited
binding phase (146). The Binding rate (slope) represents the rates dependent on the
antibody concentration but not binding kinetics. This is distinctly observed in the binding
response curve from titration of known concentration of anti-HA (NR-42019) monoclonal
antibodies in Fig. 2.9 A.
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Fig. 2.9. Determination of association, dissociation rate, and maximum binding of antiHA mAb to recombinant HA protein. A). An SPR sensogram of binding of Anti-HA mAb
(2.08 nM to 33.33 nM, (a-e)) to immobilized HA protein. The binding is recorded as
Response units (RU). B). A graph showing maximum binding units (MBU) for different
concentrations of anti-HA mAbs (a-e), and C). Binding rate constants determined using
the trace drawer software.
A logarithmic relationship was observed between maximum binding units (MBU)
vs. concentration of anti-HA mAbs (Fig. 2.10A) (R2=0.9927). The calibration curve of
known anti-HA monoclonal antibodies was used to calculate the relative concentration
(equivalent nM) of HA-specific antibodies in polyclonal serum collected from the
immunized pig, as mentioned previously (145). The serum from the immunized pigs from
each group was pooled, filtered, and diluted to 1:10 before injecting over the immobilized
HA protein on a sensor chip. The specific binding of anti-HA antibodies from the serum to
the HA protein on the sensor was recorded after baseline was stabilized with 10 % serum
from non-immunized pigs (naïve pigs). From the MBU values obtained from the
sensogram of polyclonal serum antibodies, the relative anti-HA antibody concentration in
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the serum was calculated (Fig. 2.10 B) using the standard curve prepared using anti-HA
mAbs (R2=0.993; Fig. 2.10 A) (145). Serum from the pigs immunized with InAc-NPs as
an adjuvant showed 6.27 times more anti-HA antibodies compared to saline as an adjuvant
(Fig. 2.10 B). Similar to the data shown using ELISA (Fig. 2.7), SPR data also indicates
high antigen-specific antibody titers for both InAc-NPs and Addavax as adjuvants. The
strength of antibody-antigen binding is indicated by the KD value. Most antibody-antigen
interactions have KD values in the range of 1E-6 to 1E-10M. The affinity and rate kinetics
also indicate that InAc-NPs generated a high-quality antibody in the serum that binds to
the target antigen at a nanomolar affinity (3.49E-09 M). The strength of binding of serum
antibodies generated by InAc-NPs as an adjuvant is comparable to anti-HA mAbs and
serum antibodies generated by a commercial adjuvant Addavax. In contrast, when adjuvant
is not used during vaccination (saline), the concentration of serum anti-HA antibodies, as
well as their affinity towards the antigen, is very low (Fig. 10C). For establishing the
avidity of serum antibodies, HA protein was selected instead of M2e because of high serum
titers observed against HA antigen (Fig. 2.7). Although InAc has been shown to be superior
in activating mice immune cells compared to pig immune system, the avidity of mouse
antibodies has yet to be investigated.
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Fig. 2.10. Quantification of serum antibodies concentration and affinity. A). Calibration
curve of antibody binding was derived from titrating the commercially available anti-HA
mAbs by considering maximum binding (RU) as a parameter, B). The HA-specific
antibodies concentration from unknown serum samples from the experimental group was
calculated from the calibration curve with possible total binding combinations (avidity)
(n=3, experimental triplicate), C). The curve-fitting analysis 1:1 dissociation model
(Langmuir model) was applied and calculated the association rate constants (ka),
dissociation rate constants (kd), and equilibrium rate dissociation constant (KD) from the
immunized serum.
Influenza viruses significantly affect the health of humans, livestock, and several
wild species. Controlling the infections in swine is very important for not only preventing
the economic loss to the swine industry across the globe but also preventing zoonotic
transmission to humans, which was observed during the 2009 “Swine Flu” outbreak. Swine
influenza, like in humans, cause high morbidity in pigs along with respiratory illness that
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is characterized by coughing, sneezing, fever, and loss of appetite (147). In addition to the
weight loss, influenza infection is also connected to higher abortion rates and smaller litter
size in breeding sows (148). Vaccination is the only major medical intervention for
influenza that can be translated to the large population. Current commercial swine vaccines
are focused on inactivated whole viruses. Just like in humans, swine influenza vaccines
also face challenges due to the presence of high number of genetic variants and difficulties
in predicting the upcoming variant(s). Although, the final direction for all Influenza
vaccine researchers is to design a universal influenza vaccine, it is far from a reality in the
near future (149). Recently, M2 protein and nucleoprotein (NP) was being investigated as
a vaccine antigens for broader protection than frequently mutating surface proteins such as
HA and Neuraminidases (149). However, these proteins are weakly immunogenic and
require a strong vaccine adjuvant. As shown in this study, the use of a selective TLR4
agonist such as InAc as an adjuvant and delivery system may be possible to provide broader
protection against influenza.

2.4. Conclusion
In the present study, we investigated the ability of InAc-NPs as a vaccine adjuvant in pigs
using influenza antigens. InAc-NPs have produced high serum antibody titers that have a
high affinity to the targeted antigen. Further, InAc particles protected the degradation of
HA antigen for at least 12 months when stored at 4oC. This study is a proof-of-concept
study, for the first time shows the ability of InAc as an adjuvant and a vaccine delivery
system in pigs. The findings of this work will not only pave the way to significantly improved
pig influenza vaccines but also provide a new platform technology for other viral vaccine
formulations for both pigs and perhaps even for humans.
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CHAPTER III
A Stable Oral-Vaccine Delivery System and Adjuvant for Influenza
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3.1. Introduction
Most viruses responsible for infectious diseases will enter by mucosal surfaces (150). The
mucosal areas of gastrointestinal, genitourinary tracts, respiratory, and the ear cavity
include a large surface area (approximately 400m2) of mucus membranes lining (151). Due
to their physiological nature, these cavities are prone to the external environment and
susceptible to opportunistic infections. About 70% of pathogens are known to enter the
host by mucosal surfaces (152). The mucosal surfaces comprise massive immunological
surveillance. This constant observation enables the innate and adaptive mucosal immune
system to defuse possible threats from the external environment (153). The most efficient
strategy to protect these mucosal surfaces from viral infections is vaccines. Vaccines
reduce the global burden of infectious diseases, such as preventing diseases like pertussis
polio and eliminating smallpox (154, 155). Most vaccines are administered via parental
routes, which induce a systemic immune response. Systemic immunity, in general, is not
potent enough to restrict the entry of pathogens via mucosal surfaces (156). The mucosal
vaccination, such as oral vaccination, could provide mucosal immunity, indicated by the
generation of secretory antibodies (sIgA) and systemic immunity, and acts as the first line
of defense during the entrance of the virus through mucosal surfaces.
However, oral vaccines must encounter a harsh environment composed of gastric
fluids after administration. Vaccines face the challenge of surviving in the GI tract under
highly acidic pH conditions and intestinal enzymes, including proteases. Subsequently,
vaccines need to reach the GALT by overcoming the physical and chemical barriers that
influence their internalization. Moreover, oral vaccines have to overcome the tolerogenic
responses present in the intestinal tract, which suppresses vaccine efficacy (154).
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Therefore, oral immunization is relatively not successful. There are two approaches
showing promise to overcome these obstacles: entrapping of antigens in the protective
delivery system from degradation (nanovaccine), which promote uptake and or target of
vaccines to particular regions or cells in the GIT.
Limited mucosal vaccines have been approved, especially oral vaccines, for human
consumption, including the polio vaccine for rotavirus and cholera (153). So far, these
approved vaccines are whole pathogens, either inactivated or live-attenuated. Therefore,
they are prone to the risk of virulence, and extensive quality control measures are to be
considered during production. There is a need for safe and effective vaccines to overcome
this re-emerging of virulence from traditional mucosal vaccines. One of the effective
strategies is to explore the subunit vaccines. The rationale for subunit vaccines is that the
vaccine comprises only viral components that elicit a protective immune response.
However, these subunit vaccines are poorly immunogenic compared to traditional whole
virus vaccines, which may be due to conventional whole virus-containing vaccines having
immunostimulatory components known as pathogen-associated molecular patterns
(PAMPS).
The lack of PAMPS in subunit vaccines demanded the need for vaccine adjuvant
to augment the vaccine response. The adjuvants are typically classified as
immunopotentiators or delivery systems, while some have both properties (151). Some of
the adjuvants are PAMPS or modified forms of PAMPS from known microbes. Inulin
acetate is a plant-based polysaccharide discovered in our laboratory previously known for
its activation of immune cells via TLR4 (50, 52, 157).
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Besides as a potent vaccine adjuvant, nanoparticles prepared with InAc as a
polymer will have unique properties that could qualify them as an oral vaccine delivery
system. Inulin acetate is water-insoluble, and its backbone structure (poly-fructose with
beta (2-->1) linkages in linear chains) will not be degraded by known gastric enzymes or
conditions. Therefore, it is expected not to release its encapsulated antigens within the GI
transit time. Further, being a particulate in nature and prepared with a TLR4 agonist, InAcNPs are expected to be taken up by APC in the GI tract. In this study, for the first time,
Inulin Acetate (InAc) is proposed as a nanoparticle system to deliver the encapsulated
antigen orally in mice with a peptide from influenza-A nucleoprotein (Inf-A) as a model
antigen and evaluated its ability to stimulate a mucosal immune response.

3.2. Materials and methods
3.2.1. Materials
Inulin (cat# 198971) and polyvinyl alcohol (cat# 151937) were purchased from MP
Biomedicals, Solon, Ohio. Poly (D, L-lactide-co-glycolide) (Resomer® RG 503,
cat#739952), albumin from chicken egg white, lyophilized powder (cat# A5503), and
albumin from bovine serum (cat# A3059) was obtained from Sigma-Aldrich, St. Louis,
MO. The Monophosphoryl lipid A (MPLA) was purchased from InvivoGen, San Diego,
CA,

USA.

DAF-FM

diacetate

(3',6'-bis(acetyloxy)-4-amino-2',7'-difluoro-5-

(methylamino)-spiro[isobenzofuran-1(3H),9'-[9H] xanthen]-3-one, cat# 18767), was
purchased from Cayman Chemical, Ann Arbor, Michigan. Fluorescein isothiocyanate
isomer I (cat# sc-206015A) was purchased from Santa Cruz Biotechnology, Inc. Dallas,
TX. BD detergent solution concentrate (cat# 660585), BD sheath additive (cat# 660584),
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and BD FACS clean (cat# 340345) were purchased from BD Biosciences, San Jose,
California. All the other chemicals were purchased from Fisher Scientific, Waltham, MA,
USA.

3.2.2. Cell lines and animals
Mouse macrophage cells derived from primary bone marrow cells were sponsored by BEI
Resources, ATCC, Manassas, VA, USA (NR-9456 & NR-9458). Macrophages were
cultured in DMEM-high glucose medium (Hyclone Laboratories, Logan, Utah) and
supplemented with antibiotics (gentamycin and penicillin/streptomycin) and 10% fetal
bovine serum (FBS). Balb/c mice were purchased from Taconic Biosciences, IN, USA.

3.2.3. Reverse phase HPLC method for the quantification of Inf-A peptide
HPLC analysis was conducted using the Waters HPLC system (Milford, MA, USA) with
a W2998 PDA detector. A gradient method with the conditions described (Table.3.1) was
used to elute the peptide in the reverse phase using Eclipse XDB-C18 4.6×150mm. Mobile
phase-A contains 0.05% TFA in water, and mobile phase B has 0.01% TFA in acetonitrile
with a constant flow rate of 0.7 mL/min; the sample injection volume was 20µl, and the
eluted peptide was detected at 220 nm wavelength. A standard curve was prepared from
the chromatograms obtained from a known amount of the Inf-A peptide (n=3), which was
used to determine the unknown amounts in the sample.
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Table. 3.1. Gradient conditions for elution of Inf-A peptide
Time (minutes)

Flow rate

Mobile phase-A

Mobile phase-B

0.0

(mL/min)
0.7

80.0%

20.0%

5.0

0.7

25.0%

75.0%

10.0

0.7

80.0%

20.0%

3.2.4. Nano vaccine formulation
Antigen (Inf-A) loading into InAc-NPs was achieved by double (w/o/w) double emulsion
solvent evaporation technique as described in Chapter II (section 2.2.4) with minor
modifications. Inf-A antigen (5.0mg) was dissolved in the aqueous phase and added
dropwise to the organic phase containing 100mg of InAc during the primary emulsion.

3.2.5. Scanning electron microscope (SEM)
The morphology and size of InAc-NPs were examined using scanning electron microscopy
as described previously in (49, 50).

3.2.6. Quantifying the antigen loading of InAc-Inf-A-NPs
A weighed amount of antigen-loaded NPs was added to the acetone (0.5 mL) to dissolve
the polymer. The precipitated Inf-A peptide (antigen) was pelleted by centrifugation, and
the collected pellet was dissolved in 10 mM PB, pH 7.4. The concentrations of extracted
Inf-A peptide in solution were determined by HPLC (section 3.2.3). The results are
reported as microgram of antigen per milligram of InAc-NPs.
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3.2.7. Stability of InAc-NPs in gastric fluids: diffusion of the cargo
The InAc-NPs loaded with Fluorescein sodium dye (3 µg equivalent of dye) were
dispersed in three media; deionized water, simulated gastric fluid (SGF), and simulated
intestinal fluid (SIF). The dispersed samples were incubated at 100 rpm; 37oC, and samples
were collected at pre-determined intervals. The samples were centrifuged at 20,000g, and
the supernatant solution was analyzed using a fluorimeter at excitation of 460nm and
emission of 515nm.

3.2.8. Stability of InAc-NPs in gastric fluids: surface erosion of the particles
The weighed amount (3mg/5mL) of blank InAc-NPs was dispersed in simulated gastric
fluid and intestinal fluid incubated at 37oC at 100 rpm using an orbital shaker. At prconcluded time intervals, the sample was collected and centrifuged at 20,000g, and the
pellet was resuspended in 10mM PB, pH 7.4, and measured the size of particles using DLS.

3.2.9. Stability of antigen in encapsulated InAc-NPs
The InAc-Ova-NPs or Ovalbumin protein (Ova) were dispersed in three media: a) SGF and
b) SIF, and c) 10 mM PB, pH 7.4. At pre-determined intervals, samples were collected,
and the Ova was extracted as described in section 2.2.7. Four micrograms (µg) of
equivalent protein samples were loaded onto 10% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE, 10 %). After separating the proteins, the gels were stained with Coomassie
Brilliant Blue (R-250) (0.25%) as described by the manufacturer.
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3.2.10. Release of Inf-A peptide from InAc-NPs
The Inf-A- NPs (1mg/mL) were dispersed in 0.1M phosphate-buffered saline (PBS) at pH
7.4 and incubated at 37oC at 100 rpm using an orbital shaker. The samples were collected
and centrifuged at 20,000g for 20 minutes at pre-determined time intervals. The samples
supernatants were filtered (0.2 µm), and the amount of Inf-A released was determined by
RP-HPLC as described in section 3.2.3.

3.2.11. Internalization of InAc-NPs by murine macrophages
The uptake of InAc-NPs containing FITC-Ova by mouse macrophages was evaluated by
flow cytometry. The labeling of Ovalbumin with FITC is conducted as described under
section 2.2.3. The murine macrophage cells (1 × 106/well) were seeded in a 24-well plate
and incubated with the following groups: no treatment (only media), InAc-FITC-Ova-NPs,
or PLGA-FITC-Ova-NPs for 1hr at 37oC. The amount of antigen added is normalized to
25 g/well using the fluorescence of FITC. After incubation, cells were washed three times
and trypsinized to make a single-cell suspension. Subsequently, the percent of cells
containing FITC-Ova and the relative number of FITC-Ova per cell were analyzed using
flow cytometry.

3.2.12. TLR4 activation assay
TLR4 specific activation vt InAc-NPs was investigated using bone marrow-derived mouse
wild type (WT) and TLR4 knockout (TLR4–/–) mice. The cells were treated for 48 hrs
without antigen, blank PLGA-NPs or InAc-NPs (250 μg/mL), and MPLA (2 μg/mL) was

66
used to compare the results. The supernatant was collected and centrifuged at 20,000g and
determined the Interleukin-6 (IL-6) levels (52).

3.2.13. Intracellular nitric oxide estimation
Mouse macrophages were seeded in black cell culture plates and incubated with the
treatments mentioned in section 3.2.12. After 12 hrs, the cells were washed with 1X PBS,
and the cells were incubated for 2 hrs with 10 μM DAF-FM diacetate in an FBS-free
medium. Later, the cells were washed 4 times with 1X PBS, and the intracellular
fluorescence was measured at an excitation and emission at 485/520 nm (52).

3.2.14. Mice immunization
The Balb/c mice (10-weeks old and mixed-gender) were purchased from Taconic
Biosciences, IN. Upon arrival, mice were divided into three groups with equal males and
females for acclimatization in laboratory conditions for one week. After one week, mice
were fasted overnight and performed the oral gavage with 50µl saline (group 1), 100 µg
Influenza A peptide (Influenza A NP (366-374) Strain A/PR/8/35 peptide, GeneScript, NJ)
(group 2), or InAc-Inf-A-NPs containing 100 µg Influenza A peptide (group 3). A booster
dose for oral vaccination was given after one week while blood was drawn at 0 days, one
week, two weeks, and four weeks of initial vaccination from the tail vein. Mice were
sacrificed at four weeks of immunization; intestine, lung, and spleen were collected and
snap freezed in liquid nitrogen to measure tissue-specific IgA titer. All animal procedures
were conducted per the approved IACUC protocol at Arkansas Tech University, AR.
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3.2.15. Measuring Inf-A specific IgG and IgA concentration in serum
Blood collected at 0 days, one week, two weeks, and four weeks of vaccination was used
to separate serum. Serum was analyzed for Inf-A specific (IgG) concentration using
comparative ELISA/ Influenza A Virus NP Antibody Inhibition ELISA (Virusys
Corporation, MD) as per manufacture protocol. Obtained Nucleoprotein Reduction Index
(NPRI) for each sample was converted to fold change in influenza-A specific IgG
concentration compared to control (e.g., Mice fed with saline). With slight modification,
influenza-specific serum IgA was measured with IgA Mouse Uncoated ELISA Kit
(Invitrogen, MA). Briefly, the ELISA plate was coated with Influenza A peptide (Influenza
A NP (366-374) Strain A/PR/8/35 peptide, GeneScript, NJ). Influenza A peptide was
dissolved in 1x coating buffer to achieve a final concentration of 0.4 mg Influenza A
peptide/mL. A 100µl of this solution was added to all the wells, and plates were incubated
at 4 °C overnight. After incubation plate was washed and blocked as per recommended
protocol. IgA standard and serum samples were diluted in assay buffer and added to
respective wells while assay buffer was added to wells to determine background. After
incubation for 2 hours, plates were washed four times, and detection antibodies were added
to each well. After 1-hr of incubation, plates were washed four times, and a 100 µl substrate
was added to each well. The reaction was stopped by adding a 100 µl stopping solution,
and plates were analyzed for optical density (OD) at 450 nm. OD values for standards
were used to estimate each sample's Influenza A specific antibodies.

3.2.16.

Measuring total and Inf-A-specific IgA concentration in the small

intestine (ileum), lungs, and spleen
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To measure the Inf-A specific IgA concentration in mucosal tissue, the distal part of the
ileum (2 inches segment from the ileocecal junction) and all lobes of the lungs were
collected at four weeks of vaccination. Tissue samples were snap-freezed in liquid nitrogen
and stored at -80 °C until analyzed. During analysis, frozen tissue was weighed and
homogenized in phosphate-buffered saline (1XPBS, pH 7.4) to achieve a 200mg/mL final
concentration. Tissue homogenate was centrifuged at 8000 rpm for 3 minutes to collect
supernatant containing IgA. Protein concentration in each tissue supernatant was measured
using the Pierce BCA protein assay kit (Thermo Fisher Scientific, MA) and normalized as
100mg/mL. Influenza-specific serum IgA in homogenized tissue supernatant was
measured using IgA Mouse Uncoated ELISA Kit (Invitrogen, MA) with slight
modification and converted to IgA/gram of tissue.

3.2.17. Hemagglutination inhibition assay (HI assay) to measure influenza-A
specific antibodies in the ileum and lungs
Influenza A Virus, A/Puerto Rico/8-9NMC1/1934 (H1N1) (kindly provided by BEI
Resources, NR-29023) was used to measure the Inf-A specific neutralizing antibodies in
the tissue using HA-HI assay as a method described earlier (158). Influenza A virus was
diluted in PBS to obtain its final concentration as 4 HA units using 1% chicken red blood
cells (Innovative Research Inc, Novi, MI). A 25 µl supernatant of tissue homogenate was
serially diluted two folds in a round bottom 96 well plate with 1X PBS, while 1X PBS
alone was used as a negative control. An equal amount of influenza virus (25 µl: 4 HA
unit) was added to each well and incubated for 30 minutes for virus neutralization. After
30 minutes, 1% chicken red blood cells were added to all wells and incubated for another
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30 minutes. The highest tissue homogenate dilution with “bottom” formation was used to
estimate the sample's HI unit for Influenza A virus-specific antibody.

3.2.18. Statistical analysis
The results were expressed as mean ± standard deviation (SD). The variance between
groups was compared using Student’s t-test or one-way ANOVA as required, followed by
Bonferroni's post-hoc multiple comparison tests. The data was analyzed in Instant graph
pad prism software (CA). P<0.05 was considered a statistically significant difference
unless specified under figure legends.

3.3. Results and Discussion
Influenza vaccines provide the protection by producing neutralizing antibodies
against the virus surface glycoproteins hemagglutinin (HA) and neuraminidase (NA).
Annually, mutations in influenza viruses lead to the antigenic drift and shift especial in HA
and NA genes. Thus, developing cross-reactive influenza vaccines against influenza
viruses is essential. Several peptides from nucleon protein (NP) or a transmembrane protein
M2 have been tested for providing protection against broader strains of influenza (159). In
this

study,

Inf-A

peptide

(a.a.

366–374)

from

Influenza

strain

A/PR/8/35

(ASNENMETM)) was selected as an antigen due to its ability to elicit CD8+ T cell
response to influenza virus and the generation of anti-viral cytokines (IFN-γ and TNF-α)
(160, 161). Peptide antigens are weakly immunogenic, including Inf-A peptide, which
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require vaccine adjuvants in the formulation (121). The current study used an Inf-A peptide
as a model antigen and InAc-NPs as a vaccine adjuvant and delivery system.

3.3.1. Physicochemical characterization of the InAc polymer and vaccine
formulation
The size of InAc-Inf-A-NPs was around 515 ±0.86 nm in average diameter and with a
slight negative charge of -0.9 ± 0.21 mV as determined by dynamic light scattering (DLS)
(Figure 3.1A, B). Additionally, the shape and size were confirmed by SEM (Fig. 3.1 C).
The amount of antigen (Inf-A) present in InAc-NPs was analyzed using an RP-HPLC
described in section 3.2.3. Approximately, 15.43±0.7 µg/mg of Inf-A peptide was loaded
in InAc-Inf-A-NPs.
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Fig. 3.1. Characterization of InAc-Inf-A-NPs. A). The mean particle size distribution
was measured using DLS and represented as intensity (percent). B). Zeta potential shows
an illustration of surface charge, which is close to a neutral charge (-0.90.2 mV). C).
The morphology of InAc-NPs as shown by scanning electron microscopy (SEM). The
InAc polymer is a hydrophobic polysaccharide-based TLR4 agonist and activates Tolllike receptors on APCs to release cytokines which were previously studied.

3.3.2. InAc-NPs protect the antigen in gastric conditions
Orally delivered nano vaccines will encounter a harsh environment, increased or triggered
enzymatic activity, a shift in acidic pH, or reductive or oxidative conditions (162). The
most vital task of nanoparticles in the oral vaccine delivery system is to protect
protein/peptide molecules from the GIT enzymes and deliver encapsulated protein to the
desired cells. For a antigen to be protected the particulate delivery system should not
release the antigen in the gastric fluids. The encapsulated material from the hydrophobic
polymeric particles is released by two different mechanisms; a) it is released due to surface
erosion of the polymeric matrix through the cleavage of chemical bonds at the exterior, and
b) by diffusion of the physically entrapped drug (163).
The InAc polymer is hydrophobic, suggesting surface erosion controls the drug
release (164). The stability analysis of blank InAc-NPs in simulated gastric and intestinal
fluid (n=3) was performed based on the nanoparticles' size and measured by DLS. If there
is a surface erosion, you expect a decrease in the size of the particles with respect to time
of incubation. The sizes and PDIs of both InAc and PLGA-NPs were not significantly
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altered (Fig. 3.2) as we incubated them in SIG or SIF for up to 12 hrs., which suggests that
the particles are stable in SGF and SIF.

Fig. 3.2. Stability of InAc-NPs against erosion. The InAc and PLGA blank particles
were dispersed in a) SGF and b) SIF at ~100 rpm, 37 °C. Dispersed samples were
collected and measured for particle size at pre-determined time intervals using DLS. Data
represent mean ± standard deviation (n=3).

To check whether InAc-NPs prevent the pre-mature release of the antigen in the
gastric environment, the stability of InAc NPs in the gastric fluids and the release of the
encapsulated cargo through diffusion are studied. The InAc-NPs loaded with Fluorescein
sodium released negligible amounts of the encapsulated cargo (Fluorescence sodium) in
Di water (0.8%), SIF (0.1%), and SGF (0.04%), respectively, by 24 hrs (Fig.3.3). This data
suggests that the InAc-NPs are stable, and there is no diffusion of the cargo in the time
studied.
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Fig. 3.3. Stability of InAc-NPs in preventing premature release of the cargo. Release
of Fluorescein sodium from InAc-NPs. InAc-NPs (3 mg/mL) were dispersed in a) DI
Water, b) Simulated Gastric Fluid (SGF), or c) Simulated Intestinal Fluid (SIF) at ~100
rpm, 37°C. Fluorescein concentration in the supernatant solution at different time points
was measured using a fluorimeter at excitation and emission wavelengths of 460 nm and
515nm, respectively. Data represent mean ± standard deviation (n=3).

3.3.3. Inf-A release kinetics by InAc-NPs
Peptide and polymer interaction study is critical to formulating a nanovaccine system in a
sustained release delivery system so that the desired antigen release can be achieved (165).
The cumulative amount of Inf-A released from the InAc-NPS was determined in 10mM
PB, pH 7.4. The Inf-A peptide concentration was estimated using RP-HPLC, as mentioned
in section 3.2.3.
We found a burst effect within the first 60 minutes for all systems below 20% of
the loaded peptide. This can be associated with the surface adsorbed peptide having
immediate contact with the buffer and dissolved into the solution. Over the 12 days of
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duration, we observed the cumulative release of peptides of around 80% in the solution
(Fig.3.4). This is advantageous for the nanovaccine delivery system to release the antigen
constantly.

Fig. 3.4. In-vitro antigen (Inf-A) release from InAc-NPs. Calibration curve for Inf-A
peptide (panel A) and in-vitro antigen (Inf-A) release kinetics from InAc-NPs (Panel B);
The calibration curve (panel A) was plotted from the area under the curve of the peptide
peak vs. the amount of the peptide. For panel B, InAc-NPs (1 mg/mL) were dispersed in
0.1M PB, pH 7.4 at ~100 RPM. Inf-A concentration in the soluble fraction was measured
at different time points by using HPLC (n=3) as described in section 3.2.3.

3.3.4. Internalization of InAc-NPs by murine macrophages
The nanosized InAc particles mimic the size and shape of viruses or pathogens. Further,
the TLR4 agonistic activity of the InAc particles functions as PAMPs to enhance the
recognition and interaction by APCs such as macrophages and dendritic cells.
Nanoparticles encapsulated with a fluorescent antigen (FITC labeled Ovalbumin)
were prepared using InAc or PLGA as a polymeric matrix. The uptake of these particles
by murine macrophages was quantified by flow cytometry (Fig. 3.5). The data suggest that
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the percentage of uptake in the cell is higher for InAc-FITC-Ova-NPs vs. PLGA-FITCOva-NPs.

Fig. 3.5. InAc-NPs uptake by murine macrophages. The InAc-FITC-Ova-NPs or
PLGA-FITC-Ova-NPs (25µg equivalent to FITC-Ova) were added to 100,000 cells. After
1hr incubation, the cells were analyzed by flowcytometry for the presence of green
fluorescence. The experiments were performed in triplicate, and data were represented as
mean ± standard deviation.
Table. 3.2. Quantification of antigen delivery to mouse macrophages
S.No.

Treatment groups

Mean fluorescence

% Green cells

intensity (counts)
1.

Media

5678.48 ± 346.15

10.92 ± 3.80

2.

PLGA-FITC-Ova-NPs

21828.27 ± 2018.09

84.19 ± 4.20

3.

InAc-FITC-Ova-NPs

13958.40 ± 253.80

99.80 ± 0.05*
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The data from Fig. 3.5. was quantified and reported. Data represent the mean ± standard
deviation (n = 3). * p < 0.05 InAc-FITC-Ova-NPs vs. PLGA-FITC-Ova-NPs using one
way-ANOVA followed by Bonferroni's multiple comparison test.

3.3.5. Stability of antigen (Ova) InAc-NPs in SGF and SIF
The InAc-NPs were loaded with the Ovalbumin (OVA) as a model protein antigen to
evaluate the impact of the formulation on protecting the antigen integrity from the harsh
environment. After the InAc-NPs were pre-treated for 30 minutes with 10 mM, PB, pH
7.4, the particles were incubated in SGF and SIF for 30 minutes and 2 hrs. The Ova was
extracted from the treated In-Ac-Ova-NPs as described in section 3.2.6. After the protein
extraction from InAc-NPs, the concentration was calculated using micro-BCA as per
manufacturer instructions. The SDS-PAGE was performed on the protein samples to
evaluate any change in molecular weight of the protein or degradation. Compared with the
pure OVA protein band, the data suggested OVA was intact during antigen loading to
InAc-NPs and upon exposure to SGF and SIF. The SDS-PAGE showed no additional
bands, indicating the absence of the aggregates or fragments besides the bands observed in
untreated OVA (166). However, there is a decrease in the band intensity for the NPs treated
with SIF; this could be due to the pancreatin enzyme present in the intestinal fluid (Fig.3.6).
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Fig. 3.6. Protection of antigen (Ova) by InAc-NPs in SGF and SIF. The InAc-Ova-NPs
or pure Ova protein was incubated in10 mM PB, pH 7.4 (a), SGF (b), and SIF (c). At
different time points, as shown in the figure, the antigen (Ova) was isolated and separated
by SDS-PAGE and detected by Coomassie blue. Gel 1 represents Ova protein solution,
and gel 2 represents Ova protein encapsulated in InAc-NPs.

3.3.6. TLR4 selective activation by InAc-NPs
An in vitro assay was conducted to investigate the activation of mouse macrophages by
InAc-NPs. Upon activation, macrophages releases lipids, cytokines, and nitric oxide. We
studied the proinflammatory cytokine (IL-6) production in the supernatant and analyzed
for nitric oxide production (Fig. 3.7A). The InAc-NPs were able to activate the mouse
macrophages and produced significant levels of IL-6 compared to the PLGA-NPs. The
PLGA was chosen because of its inert activity in the stimulating immune cells. In contrast,
InAc-NPs failed to stimulate the TLR4 knockout macrophages (Fig. 3.7B). This indicated
the specific activation is TLR4 dependent. MPLA was used in the experiment as a positive
control for TLR4 activation. From our laboratory, we showed the immune activation
properties of InAc on different types of APCs through TLR4 (49). For the first time, we
investigated the stimulatory effect of InAc-NPs on in mouse macrophages.
A.

B.
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Fig. 3.7. Activation of macrophages by InAc-NPs. The activation effect of InAc-NPs on
TLR4 was examined using mouse macrophage cell lines (WT and TLR4 -/-). The cells
were incubated with InAc-NPs or PLGA-NPs (no antigen) for 48 hrs. MPLA (known TLR4
agonist) was used as a positive control. The stimulation of macrophages was evaluated by
assessing the levels of panel A). nitric oxide and panel B). interleukin-6 (IL-6) in the culture
supernatants. The significant difference between groups was measured by paired t-tests
compared to InAc-NPs or MPLA treatments of Ø WT cells versus MPLA or InAc-NPs
treatment of Ø TLR4 (−/−) cells at a 95% level of significance. (*p<0.05).

3.3.7. Antigen delivery by InAc-NPs generated strong secretory (sIgA) antibody
titers
Extensive vaccine research is underway to develop needle-free platforms; a few delivery
systems include live recombinant bacterial and viral vectors. The vectors used for delivery
are inert and not capable of generating immune responses (167). Live bacterial or viral
vectors induce sIgA via various mechanisms depending on the PAMPs they stimulate and
the type of the cargo (for example, cytokines) they deliver together with the antigen. The
non-living delivery systems such as nano- and microparticles, nanogels, or liposomes do
not possess the possible safety concerns usually observed in the whole live pathogen. Many
non-living carriers induce SIgA after mucosal immunization either by oral, vaginal, or
nasal routes (168, 169). Secretory IgA (sIgA) plays a crucial role in host defense against
respiratory pathogens by inducing mucosal immunity (170).
After immunization of mice groups with saline, Inf-A peptide in saline solution,
and InAc-Inf-A-NPs, the mice were sacrificed after four weeks, and the tissues were

79
collected. Saline, Inf-A peptide in saline solution, and InAc-Inf-A-NPs elicited antigenspecific IgA antibody responses in homogenized organs (Fig.3.8 A). In Lung homogenate,
compared to the titer elicited by Inf-A peptide alone, the titers were ̴2 fold higher for the
InAc-Inf-A-NPs formulation; in the intestine (Ileum) homogenate, compared to the titer
elicited by Inf-A peptide alone, the titers were 2̴ fold higher for the InAc-Inf-A-NPs
formulation. However, the control mice immunized orally with saline had background
titers similar to the peptide solution; this could be because the mice before the experiment
were exposed to any other respiratory pathogens. In turn, it generated the secretory
antibodies.
On the other hand, we conducted the sandwich ELISA to evaluate the total IgA in
the Intestine (Ileum), Lung, and spleen homogenates (Fig. 3.8 B). In Lung homogenate,
compared to the titer elicited by Inf-A peptide alone, the titers were ̴1.3 fold higher for the
InAc-Inf-A-NPs formulation (P < 0.05), In the intestine (Ileum), homogenate, compared to
the titer elicited by Inf-A peptide alone, the titers were ̴1.6 fold higher for the InAc-Inf-ANPs formulation (P < 0.05). The same background was observed in the mice immunized
with mice alone as in antigen-specific IgA. However, there is no difference between the
treatments in the spleen.
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Fig. 3.8. Total IgA (panel A) & Inf-A specific IgA (panel B) antibody response in the
tissues following oral vaccination. Balb/c mice were orally administered with saline,
peptide alone in saline, or InAc-Inf-A-NPs for immunization. After four weeks, the mice
were sacrificed, and the tissues were collected. The tissue samples were homogenized in
protease inhibitor and normalized for equal protein concentration followed by measuring
the concentration of anti-Inf-A IgA and total IgA by sandwich ELISA. * p < 0.05 InAcInf-A-NPs vs. saline or peptide using one way-ANOVA followed by Bonferroni's
multiple comparison test.

3.3.8. Antigen delivery by InAc-NPs generated strong antigen-specific IgG and
IgA antibody titers
B cell responses play a key role in adaptive immunity to a viral infection (171). sIgA
antibodies mediate viral neutralization and are involved in distinctive roles in immunity
from the entry of pathogen at distal sites (172). Following the vaccination by Saline, Inf-A
peptide in saline solution, and InAc-Inf-A-NPs, the serum was collected at 1 and 4 weeks
of immunization for Inf-A (antigen) specific IgG (Fig. 3.9 A). The Serum was analyzed for
influenza-A specific (IgG) concentration using comparative ELISA/ Influenza A Virus NP
Antibody Inhibition ELISA. The titers from the saline-treated mice have the same
background after two doses of vaccine admonition. At the same time, the serum titers were
collected after one week of primary vaccination. We observed antigen-specific IgG
response in peptide alone and InAc-Inf-A-NPs, but there were not statistically significant.
However, in the serum collected after in 4th week, compared to the titer elicited by Inf-A
peptide alone, the titers were 1̴ .5 fold higher for the InAc-Inf-A-NPs formulation; thus, the
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data indicates with the administration of two doses of InAc-Inf-A-NPs, it is possible to
have antigen-specific antibodies production. The sandwich ELISA was conducted to
evaluate the Inf-A specific (antigen) sIgA in the serum following the immunization after
2nd dose (Fig. 3.9 B). In serum, compared to the titer elicited by Inf-A peptide alone, the
titers were ̴9 fold higher for the InAc-Inf-A-NPs formulation. The background was
observed in the mice immunized with saline alone, and this could be due to mice exposed
to other respiratory pathogens, which elicited the IgG antibodies.

Fig. 3.9. Inf-A specific IgG (panel A) & IgA (panel B) antibody response in the serum
following oral vaccination. Balb/c mice were orally administered with saline, peptide
alone in saline, or InAc-Inf-A-NPs for immunization. Two doses were given on weeks 1
and 3. The Inf-A specific IgG was quantified in serum collected at 1 and 4 weeks of
immunization (panel A). The antigen-specific IgA titers in the serum were determined on
week 4 (panel B) measured by sandwich ELISA. * p < 0.05 InAc-Inf-A-NPs vs. peptide
using one way-ANOVA followed by Bonferroni's multiple comparison test.
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3.3.9. Hemagglutination inhibition (HI)
Influenza viral surface protein HA will bind to sialic acid receptors. The virus has
other property of binding to the erythrocytes, causing a lattice formation. The lattice
formation is called hemagglutination. The RBCs have the unique property of binding to
the virus and forming a layer on the round wells; on the other hand, button formation will
be observed if the virus is not bound to the RBCs.

Fig. 3.10. Hemagglutination inhibition (HI) response following oral vaccination.
Balb/c mice were orally administered with saline, peptide alone in saline, or InAc-Inf-ANPs for immunization. A). Following four weeks, the mice were sacrificed, and tissues
were collected. The tissue samples were homogenized in protease inhibitor and
normalized for equal protein concentration. * p < 0.05 InAc-Inf-A-NPs vs. saline or
peptide using one way-ANOVA followed by Bonferroni's multiple comparison test. B).
Hemagglutination inhibition 96-well plate for better understanding of the design of the
experiment. Hemagglutination (HA), column ‘a, b’; assay showing the 2 HA units of
diluted virus (Influenza A virus, A/puertorico/8-9NMC1/1934(H1N1). Column ‘d’ shows
the Hemagglutination inhibition (HI) unit for control as zero HI units, while ‘c’ shows
more than 64 HI units in tissue lysate.
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The fundamental basis for the hemagglutination inhibition assay is that antibodies
produced against the influenza virus will inhibit the virus from binding to the RBCs. The
maximum dilution of serum that inhibits hemagglutination is called the HI titer of the
serum (173) . After immunization of mice groups with saline, Inf-A peptide in saline
solution, and InAc-Inf-A-NPs, the mice were sacrificed after four weeks, and the tissues
were collected. The HI units of homogenized organs lysate of the intestine (Ileum) and
lungs for groups saline, Inf-A peptide in saline solution, and InAc-Inf-A-NPs were reported
in (Fig. 3.10. A). In Lung homogenate, compared to the HI unit of saline alone, the HI units
were ̴3 fold higher for the InAc-Inf-A-NPs formulation. However, peptide alone in the
saline group has HI units; this could be due to the lungs being exposed to other antigens.
The generated antibodies could be interfering with the data. The antibodies in intestinal
(Ileum) lysate homogenate, compared to the titer elicited by Inf-A peptide alone, the titers
were ̴39 fold higher for the InAc-Inf-A-NPs formulation. This data suggests the InAc-InfA-NPs nanovaccine was able to induce the mucosal antibodies, and they were able to bind
the influenza virus. The picture of the experiment for both hemagglutination and
hemagglutination inhibition (HI) (Fig. 3.10 B) was reported for better understanding.

3.4. Conclusion
In the present study, we have investigated for the first time the ability of InAc-NPs
encapsulated with Inf-A antigen as an oral delivery system to elicit a mucosal and systemic
immune response as a proof-of-concept study to develop a vaccine against the influenza
virus. We observed that the antigen encapsulated in the InAc nanoparticles were robustly
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taken up by the mouse macrophages, demonstrating the ability of APCs to respond to the
presence of antigens delivered by InAc polymer as the particulate system showed a 99.80%
green cells for InAc-FITC-Ova-NPs compared to uptake by PLGA polymer, which is 84%
green cells. In addition, we demonstrate that InAc-NPs are stable in the gastric environment
and protect the model antigen Ovalbumin. Furthermore, after immunization of mice, the
presence of sIgA in the serum and mucosal tissue lysates suggests that the InAc-Inf-A-NPs
were able to elicit the mucosal immunity, and the antibodies produced demonstrated
functional activity by inhibiting the hemagglutination.
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SUMMARY AND FUTURE STUDIES
Due to the evolving respiratory pathogens (viral and bacterial), growing antibiotic
resistance, and rising occurrences of inflammatory mucosal diseases, there is an urgent
medical need to discover a safe vaccine technology that activates both systemic and
mucosal protection. However, there are limitations in the availability of vaccine
technologies or vaccine adjuvants that address the above need, which has hampered the
development of successful preventive vaccines against challenging mucosal pathogens
such as HIV, influenzas, and HPV SARS-CoV-2 virus.
Our laboratory previously reported a “Pathogen Mimicking Vaccine Delivery
System” (PMVDS) prepared with inulin acetate, a TLR4 agonist, as a polymer to generate
strong humoral and cell-mediated immunity. The main goal of this dissertation is to
investigate the potential of InAc-based nanoparticles (InAc-NPs) as a delivery system for
an oral route to generate mucosal immunity and evaluate its potential as an adjuvant and
delivery system for influenza vaccine in pigs.
As in Chapter II, subcutaneous delivery of InAc-NPs encapsulated with influenza
antigens HA and M2e generated robust systemic antibody titers (IgG) in pigs, which was
comparable to the commercial vaccine adjuvant Addavax. Various in-vitro mechanistic
investigations have shown that InAc-NPs improve the stability of the antigen during
storage and efficiently deliver it to APCs such as macrophages. Previously, our laboratory
has identified the signaling pathways of InAc activating macrophages to initiate an immune
response cascade. This is the first study that showed the efficacy of InAc as a subcutaneous
vaccine in pigs.
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This preliminary study signifies the ability of InAc-NPs as an adjuvant and a
delivery system to generate robust antibody titers in pigs. More studies are underway in
our laboratory to test the vaccine in protecting the pigs from challenges with homologous
and heterologous strains of porcine influenza. A universal vaccine that covers multiple
strains of influenza is the long-term goal of this project. Further, the technology will be
extended to other viral diseases in pigs, such as porcine epidemic diarrhea virus (PEDV),
porcine reproductive and respiratory syndrome (PRRS), and porcine epidemic diarrhea
(PED) pose a serious challenge to the productivity of today's swine farms.
Further, in chapter III, using InAc-NPs as a delivery system, we have developed an
oral vaccine with Inf-A as a model antigen and tested it in mice. InAc-Nps activated mouse
macrophages to release inflammatory cytokines necessary for vaccine efficiency. InAcInf-A-NPs generated high titers of antigen-specific sIgA (secretory and mucosal) and IgG
antibodies in serum and mucosal organs such as the intestine and lungs. The generation of
mucosal secretory antibodies by the InAc-NPs-based vaccine delivery system is significant
in designing oral vaccines against other mucosal pathogens. A significant discovery of this
aim is to identify an oral delivery system that protects encapsulated materials such as
antigens from degradation by gastric juices. In future studies, it will be tested to deliver
microbes to the colon or antigens to generate mucosal immunity. In addition, preliminary
studies were performed to explore InAc-NPs as a delivery system for other TLR agonists
and polymeric adjuvants, which could have implications for oral vaccine delivery or
subcutaneous delivery for influenza infections.
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In conclusion, the dissertation advanced InAc-based platform technology for
mucosal vaccines for animal applications vat this stage and will be advanced for human
application.
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